AD-A244 837

GRANT NO:  DAMD17-91-Z-1014

TITLE:  ASTPHLD CONFERENCE ON HUMAN RETROVIRUS TESTING IN MARCH 1991

SUBTITLE:  Sixth Annual Conference on Human Retrovirus Testing, Kansas City, Missouri, March 5-7, 1991

PRINCIPAL INVESTIGATOR:  Jerome R. Cordts

CONTRACTING ORGANIZATION:  Association of State & Territorial Public Health Laboratory Directors
12211 Connecticut Ave, NW, Suite 508
Washington, DC 20036

REPORT DATE:  January 31, 1992

TYPE OF REPORT:  Final Proceedings

PREPARED FOR:  U.S. ARMY MEDICAL RESEARCH AND DEVELOPMENT COMMAND
Fort Detrick, Frederick, Maryland 21702-5012

DISTRIBUTION STATEMENT:  Approved for public release; distribution unlimited

The findings in this report are not to be construed as an official Department of the Army position unless so designated by other authorized documents.
4. TITLE AND SUBTITLE
   ASTPHLD Conference on Human Retrovirus Testing in March 1991
   Subtitle: Sixth Annual Conference on Human Retrovirus Testing,
   Kansas City, Missouri, March 5-7, 1991

6. AUTHOR(S)
   Jerome R. Cordts

7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES)
   Association of State & Territorial Public Health Laboratory Directors
   12211 Connecticut Ave., NW, Suite 508
   Washington, DC 20036

9. SPONSORING/MONITORING AGENCY NAME(S) AND ADDRESS(ES)
   U.S. Army Medical Research and Development Command
   Fort Detrick
   Frederick, Maryland 21702-5012

13. ABSTRACT (Maximum 200 words)
   The constant evolution of testing methodologies for the human retroviruses demands
   that periodic reviews of the capabilities of these methodologies used in the public
   health laboratories be conducted. To this end, the Association of State and Territorial
   Public Health Laboratory Directors (ASTPHLD) sponsored the Sixth Conference on
   Human Retrovirus testing March 5-7, 1991, in Kansas City, MO. Approximately 285
   conference participants viewed 36 poster presentations, heard 12 plenary session
   speakers discuss a variety of topics relevant to retrovirus testing, and participated in 6
   panel sessions concentrating on the most relevant topics of human retrovirus testing.

14. SUBJECT TERMS
   Conference, AIDS, RAL
The views, opinions and/or findings contained herein are those of the author(s) and should not be construed as an official Department of the Army position or decision unless so designated by other documentation.
ASTPHLD
The Association of State and Territorial Public Health Laboratory Directors is an organization representing state and territorial public health laboratory directors throughout the United States. The Association maintains a Headquarters office and seven Area Resource Offices, and operates a National Laboratory Training Network that forms alliances among federal, state, and local health agencies and private sector organizations to develop and promote the delivery of localized laboratory training programs based on documented need. The Association also organizes and presents scientific conferences and symposia relevant to the testing activities of public health laboratories. ASTPHLD operates exclusively as a scientific and educational organization.

President:
Loris W. Hughes, Ph.D., New Mexico

Executive Committee:
Jon Counts, Dr.P.H., Washington
Gary Davidson, Dr.P.H., Ohio
Philip Haines, Dr.P.H., Maine
Katherine Kelley, Dr.P.H., Alaska
Michael W. Kimberly, Dr.P.H., Tennessee
Mahadeo P. Verma, Ph.D., Delaware

Executive Director:
Jerome Cordts, Washington D.C.
ASSOCIATION OF STATE AND TERRITORIAL PUBLIC HEALTH LABORATORY DIRECTORS

COMMITTEE ON HUMAN RETROVIRUS TESTING

David F Carpenter, Ph.D. - Illinois - Chair
Arthur F DiSalvo, M.D. - Nevada
J Mehsen Joseph, Ph.D. - Maryland
James Pearson, Dr. P.H. - North Dakota
Michael G Volz, Ph.D. - California
Jerome Cordts - Ex Officio

CONFERENCE PROGRAM PLANNING COMMITTEE

Robert Lindner, M.D., Ph.D. - Illinois - Chair
Michael S Ascher, M.D. - California
Roger Dodd, Ph.D. - Maryland
Chester R Roberts, Ph.D. - Maryland
Charles A Schable, M.S. - Georgia
Judith Wethers, M.S. - New York
Judith Wilber, Ph.D. - California

This conference was supported, in part, by a financial grant from the Department of the Army, U.S. Army Medical Research and Development Command.
Sara Beatrice, Ph.D., Director of Retrovirology and Immunology, New York City Department of Public Health, New York, New York

David F Carpenter, Ph.D., Chief, Division of Laboratories, Illinois Department of Public Health, Springfield, Illinois

Anne M Comeau, Ph.D., Co-Principal Investigator, Newborn HIV Project, Theobald Smith Research Institute, Jamaica Plain, Massachusetts

Cynthia K Cossen, Public Health Microbiologist, Viral and Rickettsial Disease Laboratory, California Department of Health, Berkeley, California

Harold Dowda, Ph.D., Director, Diagnostic Microbiology, South Carolina Department of Health and Environmental Control, Columbia, South Carolina

Chyang Fang, Ph.D., Director, National Reference Laboratory for Infectious Diseases, American Red Cross, Rockville, Maryland

J Richard George, Ph.D., Chief, Developmental Technology Section, Centers for Disease Control, Atlanta, Georgia

A Russell Gerber, M.D., Center for Infectious Diseases, Centers for Disease Control, Atlanta, Georgia

Joseph Iser, M.D., Chief Medical Officer, AIDS Program, Health Resources and Services Administration, Rockville, Maryland

J Mehsen Joseph, Ph.D., Director, Laboratories Administration, Maryland Department of Health and Mental Hygiene, Baltimore, Maryland

Stephen Josephson, Ph.D., Director, Clinical Microbiology/Virology, Rhode Island Hospital, Providence, Rhode Island

Jonathan M Kagan, Ph.D., Chief, Clinical Sciences Section, Treatment Research Program, Division of Acquired Immune Deficiency Syndrome (AIDS), National Institute of Allergies and Infectious Diseases, National Institute of Health, Bethesda, Maryland

Jonathan Kaplan, M.D., Retrovirus Diseases Branch, Centers for Disease Control, Atlanta, Georgia

Charles Konigsberg, M.D., M.P.H., Director, Division of Health, Kansas Department of Health and the Environment, Topeka, Kansas

Mary Kuhns, M.D., Chief Scientist, Abbott Labs, Abbott Park, Illinois

Dale Lawrence, M.D., Chief, Clinical Development Section, Vaccine Research and Development Branch, Basic Research and Development Program, Division of AIDS, National Institute of Allergy and Infectious Diseases, Rockville, Maryland
Francis Lee, M.D., Assistant Professor, Pediatric Infectious Diseases, Emory University, Atlanta, Georgia

Helen Lee, Ph.D., Director, Transfusion Biology Research, Abbott Laboratories, North Chicago, Illinois

Robert Lindner, Ph.D., M.D., Medical Director, Division of Laboratories, Illinois Department of Public Health, Chicago, Illinois

Shyh-Ching Lo, Ph.D., M.D., Chief, Division of Geographic Pathology, Armed Forces Institute of Pathology, Washington D. C.

Robert Martin, Dr.P.H., Director of Laboratories, Michigan Department of Public Health, Lansing, Michigan

Susan Mottice, Ph.D., Director, Microbiology, Utah State Division of Laboratory Services, Salt Lake City, Utah

Janet Nicholson, Ph.D., Center for Infectious Diseases, Centers for Disease Control, Atlanta, Georgia

John R Pfister, RM (AAM), Retrovirus Supervisor, State Laboratory of Hygiene, Madison, Wisconsin

Lt. Col. Chester Roberts, Ph.D., Chief, Diagnostic Retrovirology, Walter Reed Army Institute of Research, Rockville, Maryland

Gerald Schochetman, Ph.D., Chief, Epidemiology Branch, Division of HIV/AIDS, Center for Infectious Diseases, Centers for Disease Control, Atlanta, Georgia

Haynes W (Chip) Sheppard, Ph.D., Research Scientist, Viral and Rickettsial Disease Laboratory, California Public Health Foundation, Berkeley, California

Roy Stevens, Ph.D., Research Scientist, Wadsworth Laboratories, Albany, New York

Barbara Weiblen, M.S., Senior Scientist, Newborn HIV Project, Theobald Smith Research Institute, Jamaica Plain, Massachusetts

Judith Wethers, M.S., Director, Testing Services, Retrovirology Laboratory, New York State Department of Health, WCLR, Albany, New York

Barbara Werner, Ph.D., Director, Virology Clinical Investigation Division, Massachusetts State Laboratory Institute, Boston, Massachusetts

Judith Wilber, Ph.D., Manager, Clinical Microbiology, Nucleic Acid Chemistry, Chiron Corporation, Emeryville, California

---

4 Sixth Annual Conference on Human Retrovirus Testing
The constant evolution of testing methodologies for the human retroviruses demands that periodic reviews of the capabilities of these methodologies used in the public health laboratories be conducted. To this end, the Association of State and Territorial Public Health Laboratory Directors (ASTPHLD) sponsored the Sixth Conference on Human Retrovirus testing March 5-7, 1991 in Kansas City, MO. Approximately 285 conference participants viewed 36 poster presentations, heard 12 plenary session speakers discuss a variety of topics relevant to retrovirus testing, and participated in 6 panel sessions concentrating on the most relevant topics of human retrovirus testing.

Panel Session 1 was entitled "Testing for HIV-1". Topics discussed included rapid testing methods, Western blots, testing of non-traditional samples, surrogate markers, recombinant/synthetic based assays, Western blot interpretation criteria, indirect fluorescent antibody methods, and viral detection methods.

Panel Session 2, entitled "Polymerase Chain Reaction", discussed methodologies used in PCR, quality assurance, proficiency testing, and test interpretation and reporting.

Panel Session 3 centered on developments within "Flow Cytometry". The topics covered flow cytometry for disease staging, monitoring anti-viral therapy, training, quality assurance, reporting criteria, and interpretation.

Panel Session 4 addressed "Testing for HIV-2 and HTLV-I/HTLV-II". Topics covered HTLV-I and HTLV-II differentiation, the confirmation methodologies and criteria for HIV-1 and HIV-2 as opposed to HTLV-I/II viruses, HIV-1 and HIV-2 combination tests and alternate rapid testing methods.

Panel Session 5 concentrated on "The Diagnosis of HIV Infection in Newborns". The topics covered, in a very specific sense, the use of flow cytometry, PCR, and viral culture to enhance detection of infection in newborns. Discussions also covered the use of ELISPOT, in vitro assays and analysis for IgA.

Panel Session 6 dealt with "Standards of Practice and Reporting". A new topic covered during this session was the "Interpretation/Reporting of Reactions in Vaccinated Individuals".

There continues to be intense interest among laboratorians in the methodologies discussed in these six panel sessions due to the increased attention the medical and scientific community has focused on early intervention and treatment programs for HIV antibody positive patients. Title III of the Ryan White CARE Act outlines provisions for monitoring the immune status of HIV antibody positive patients in order to assess the stage of the AIDS disease. Laboratory analysis, in all aspects of this monitoring process, is extremely important. Laboratory findings form the basis of the therapies currently available for retrovirus infected individuals.

It is intended that the recommendations derived from the Conference on Human Retrovirus Testing be utilized universally to set laboratory standards in methodologies, policies, quality assurance, interpretation and reporting.
To assess the current status of testing for Human Retroviruses, a survey was sent to 54 state and territorial public health laboratories during the third quarter of 1990. The survey requested data for fiscal year 1990 (July, 1989 - June, 1990). In previous years, calendar year data were requested.

A milestone was achieved in gathering the data for this most recent survey. All 54 state and territorial public health laboratories and the city of New York contributed to the survey data. This had not occurred in any previous year. The summary of these data follows.

The total number of EIA tests reported by the survey participants, as indicated in Figure 1, totalled in excess of 4 million. These data cannot be compared directly to the data from previous years because they include data from 99 California clinical laboratories and blood banks and 37 county public health laboratories. However, in evaluating these data, it can be noted that the EIA reactive rate in this national sample is 3%. Western blot confirmation of the reactives was 58%; 9% of the Western blots were indeterminate. Using IFA, 79% of the reactives were confirmed and 1.5% were indeterminate.

<table>
<thead>
<tr>
<th>RETROVIRUS TESTING</th>
</tr>
</thead>
<tbody>
<tr>
<td>HIV-1</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>TEST</th>
<th>TOTAL</th>
<th>REACTIVE</th>
<th>IND</th>
</tr>
</thead>
<tbody>
<tr>
<td>E I A</td>
<td>4,424,943</td>
<td>132,376</td>
<td>N/A</td>
</tr>
<tr>
<td>W B</td>
<td>131,890</td>
<td>77,075</td>
<td>11,625</td>
</tr>
<tr>
<td>I F A</td>
<td>35,221</td>
<td>27,831</td>
<td>559</td>
</tr>
</tbody>
</table>

Figure 1. Testing reported by the members of ASTPHLD includes 37 county (local) public health laboratories and 99 clinical laboratories in California.

Removing the California data generates Figure 2, demonstrating 3.175 million EIA tests. These data exhibit a slightly higher reactive rate (3.5%). The Western Blot test confirmed 82% reactive and 7.5% were indeterminate. In utilizing the IFA, 78% of the original EIA reactive tests were confirmed while only 1.5% were indeterminate.
used most frequently, (73% of all confirmatory tests conducted). The IFA confirmatory system had been used for 26% of the reactive tests, while approximately 1% of the confirmations were conducted with either PCR or tissue culture techniques.

Figure 3 Total number of tests performed by reporting laboratories

Figure 3 indicates the total number of EIA tests done by each of the responding laboratories. These data indicate that, of the responding laboratories: approximately 48% conducted less than 50,000 tests, approximately 35% between 50,000 and 100,000 tests, and 16% conducted more than 100,000 tests for retrovirus.

Figure 4 HIV positivity rates for tests in public health laboratories

The HIV positivity rates reported by public health laboratories are shown in Figure 4. Of the responding laboratories, 42% have a low positivity rate of less than 1%, 42% of the responding laboratories indicate a positivity rate between 1 and 5% and 17% have a positivity rate in excess of 5%. The pie chart depicted in Figure 5 indicates the tests that are used to confirm EIA reactives. These data show that the Western blot test was

Figure 5 Distribution of confirmatory methods for reactive EIA

Figure 5 reveals that alternate testing methodologies are being used by more laboratories. Surrogate markers, which include p24 antigen, neopterin and beta-2-microglobulin, are used by eight laboratories. Flow cytometry, culture, PCR, recombinant antigen and synthetic peptides are also being utilized, but in fewer numbers of laboratories.
Public health laboratories continue to support the initiative of the Centers for Disease Control in gathering data for the family of seroprevalence surveys. Figure 7 indicates that 35 laboratories conducted HIV tests in populations of women of childbearing age. The data indicate that the positivity rate in this population is substantially below that seen in the adult population shown in Figure 4. Of 35 labs reporting, only 1 laboratory indicated a positive rate greater than 1%.

Figure 8 outlines the retrovirus testing being conducted in each of the responding laboratories. A total of 52 responding laboratories indicated that they conduct tests for HIV-1. Pennsylvania and Minnesota state public health laboratories do not conduct HIV testing. The data in this figure indicate 6 laboratories also conduct HIV-2 testing, and 11 laboratories perform tests for HTLV-I/II.

Figure 9 shows the number of HIV-2 tests conducted. Of the 4,460 EIA tests, only 114 (2.5%) were found to be reactive - similar to the rate seen for HIV-1. However, the Western blot confirmation rate was very different from HIV-1, in that only 11% of the EIA reactive tests were confirmed, while 16% were indeterminate. Laboratories using IFA methodologies had no reactives and only 1 indeterminate. These data appear to indicate the need to refine testing conducted for HIV-2.

Figure 10 demonstrates that of the approximately 500,000 tests conducted for HTLV-I/II less than 1% were reactive. Those reactive specimens showed a 25% confirmatory rate Western blot, while 11% were indeterminate. In utilizing IFA methodology, 55% were confirmed and 6% were indeterminate.
The principal manufacturers of EIA testing reagents are listed in alphabetical order in Figure 13. The leading suppliers of the Western blot reagents are indicated in Figure 14.

![Graph](image1)

**TESTING TURNAROUND TIME**

<table>
<thead>
<tr>
<th>Days</th>
<th>Days</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>2</td>
</tr>
<tr>
<td>3</td>
<td>4</td>
</tr>
<tr>
<td>5</td>
<td>6</td>
</tr>
<tr>
<td>7</td>
<td>8</td>
</tr>
<tr>
<td>9</td>
<td>0</td>
</tr>
</tbody>
</table>

**NEGATIVE TEST**

Figure 11 Over 80% of the public health laboratories report non-reactive EIA results within three days.

![Graph](image2)

**TESTING TURNAROUND TIME**

<table>
<thead>
<tr>
<th>Days</th>
<th>Days</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>2</td>
</tr>
<tr>
<td>3</td>
<td>4</td>
</tr>
<tr>
<td>5</td>
<td>6</td>
</tr>
<tr>
<td>7</td>
<td>8</td>
</tr>
<tr>
<td>9</td>
<td>0</td>
</tr>
</tbody>
</table>

**SUPPLEMENTAL TEST**

Figure 12 The time required to report reactive EIA varies greatly according to individual state procedures.

Figure 11 shows the average testing turnaround time when the results of the EIA tests are negative. Most laboratories indicate that results are reported within 3 calendar days. The testing turnaround time for an EIA reactive specimen is longer and more inconsistent (Figure 12). It is clearly evident that extended periods of time are needed to confirm results; the largest number of laboratories (11) indicated that 7 calendar days were needed to report a confirmed positive result. This extended turnaround time is a source of frequent discussion between the state public health laboratory and the AIDS program in each of the states and territories. Many requests have been made to consider various approaches to reduce the reporting turnaround time for confirmation of reactive EIA results.

![Table](image3)

**RETROVIRUS TESTING**

<table>
<thead>
<tr>
<th>EIA MANUFACTURERS</th>
</tr>
</thead>
<tbody>
<tr>
<td>ABBOTT</td>
</tr>
<tr>
<td>DUPONT</td>
</tr>
<tr>
<td>GENETIC SYSTEMS</td>
</tr>
<tr>
<td>ORGANON TEKNIKA</td>
</tr>
<tr>
<td>ORTHO</td>
</tr>
</tbody>
</table>

Figure 13 Suppliers of EIA reagents used by the state public health laboratories.

![Table](image4)

**RETROVIRUS TESTING**

<table>
<thead>
<tr>
<th>WB MANUFACTURERS</th>
</tr>
</thead>
<tbody>
<tr>
<td>ABBOTT</td>
</tr>
<tr>
<td>BIO-RAD</td>
</tr>
<tr>
<td>CAPPELL</td>
</tr>
<tr>
<td>DUPONT</td>
</tr>
<tr>
<td>EPITOPE (ORGANON TEKNIKA)</td>
</tr>
<tr>
<td>GENETIC SYSTEMS</td>
</tr>
<tr>
<td>ORTHO</td>
</tr>
</tbody>
</table>

Figure 14 Suppliers of Western Blot reagents used by the state public health laboratories.
HIV-1 TESTING  
US ARMY FY90

<table>
<thead>
<tr>
<th>TEST</th>
<th>TOTAL</th>
<th>REACTIVE</th>
<th>IND</th>
</tr>
</thead>
<tbody>
<tr>
<td>E I A</td>
<td>1,304,224</td>
<td>6,012</td>
<td>N/A</td>
</tr>
<tr>
<td>W B</td>
<td>6,875</td>
<td>2,278</td>
<td>863</td>
</tr>
<tr>
<td>CULTURE</td>
<td>2,417</td>
<td>1,092</td>
<td></td>
</tr>
<tr>
<td>P C R</td>
<td>657</td>
<td></td>
<td></td>
</tr>
<tr>
<td>FLOW</td>
<td>7,500</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Figure 15 US Army testing of HIV-1

HIV-2 TESTING  
US ARMY FY90

<table>
<thead>
<tr>
<th>TEST</th>
<th>TOTAL</th>
<th>REACTIVE</th>
<th>IND</th>
</tr>
</thead>
<tbody>
<tr>
<td>E I A</td>
<td>1,590</td>
<td>16</td>
<td>N/A</td>
</tr>
<tr>
<td>W B</td>
<td>16</td>
<td>0</td>
<td>1</td>
</tr>
<tr>
<td>P C R</td>
<td>5</td>
<td></td>
<td></td>
</tr>
<tr>
<td>FLOW</td>
<td>10</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Figure 16 US Army testing for HIV-2

HTLV I/II TESTING  
US ARMY FY90

<table>
<thead>
<tr>
<th>TEST</th>
<th>TOTAL</th>
<th>POSITIVE</th>
</tr>
</thead>
<tbody>
<tr>
<td>CULTURE</td>
<td>15</td>
<td>8</td>
</tr>
<tr>
<td>P C R</td>
<td>177</td>
<td></td>
</tr>
<tr>
<td>FLOW</td>
<td>100</td>
<td></td>
</tr>
</tbody>
</table>

Figure 17 The US confirmatory tests for HTLV-I/II

Figures 15, 16 & 17 represent respectively the HIV-1, HIV-2, and HTLV-I/II testing done by the US Army. Although not a member of ASTPHLD, the US Army testing laboratories represent a considerable amount of testing performed on members of the armed forces. These data are significant in that this is an excellent cross section of the young adult population of the United States. These data are not included with the survey data.
TESTING (HIV-1)
PANEL SESSION 1

ROOM: EMPIRE A/B
TIME: 8:30 TO 10:00 AND 10:45 TO 12:00, WEDNESDAY, MARCH 6, 1991
CHAIR: J Mehsen Joseph, Ph.D., Director, Laboratories Administration, Maryland Department of Health and Mental Hygiene, Baltimore, Maryland
MEMBERS: Cynthia K Cossen, Public Health Microbiologist, Viral and Rickettsial Diseases Laboratory, Department of Health, Berkeley, California; J Richard George, Ph.D., Chief, Developmental Technology Section, Centers for Disease Control, Atlanta, Georgia; Stephen Josephson, Ph.D., Director, Clinical Microbiology/Virology, Rhode Island Hospital, Providence, Rhode Island (Rapporteur)

TOPICS: Rapid testing methods; Blots; Testing of non-traditional samples; Surrogate markers; Recombinant/synthetic based assays; Simultaneous detection methods; Western Blot criteria; IFA; Viral detection methods

RECOMMENDATIONS

1.01 Rapid tests for the detection of HIV-1 antibody not be a waivered test under CLIA regulations. It is essential that a proficiency testing program be developed to ensure the quality of testing.

1.02 At the present time, we cannot recommend the use of urine or saliva specimens for HIV antibody testing. Available data, however, indicate that these specimens may be acceptable. We recommend that manufacturers and interested investigators publish in peer review journals and submit data to the FDA which would allow urine and saliva to be used for HIV antibody testing.

1.03 We encourage manufacturers to evaluate non-traditional markers such as p17 antigen and develop quantitative assays for staging.

1.04 FDA licensed recombinant or synthetic peptide ELISA tests for the detection of HIV-1 antibody can be used in an HIV-1 algorithm. The following algorithm has been proposed as an alternative to the existing algorithm for the detection of HIV-1 antibody. This algorithm should be evaluated during the coming year and data be submitted at the next meeting.

1. HIV-1 ELISA A
   a. Negative - REPORT
   b. Reactive - GO TO 2.

2. HIV-1 ELISA B
   a. Negative - REPORT
   b. Reactive - GO TO 3. or 4.

3. HIV-1 IFA
   a. Positive - REPORT
   b. Negative or Non-specific - GO TO WB and/or Follow-up specimen

4. HIV-1 WB
   a. Positive - REPORT
   b. Indeterminate - GO TO Follow-up specimen
   c. Negative - Repeat or Report

1.05 The ASTPHLD criteria for Western blot interpretation should be reevaluated in light of recent reports of uninfected individuals with envelope only or envelope and gag bands. The issue of contamination by another specimen may be a contributing factor and must be addressed.

Sixth Annual Conference on Human Retrovirus Testing 11
Quantitative antigen assays for measuring virus burden are needed to monitor disease progression and efficacy of therapy. Further development of better quantitative assays should be encouraged. It is recommended that a national reference standard for antigen quantitation be developed for use by manufacturers for standardizing their antigen detection kits.

IFA has a place in HIV diagnostic schemes as a supplemental test. Some of the currently available commercial kits show promise for use as confirmatory tests.

Laboratories with significant experience with HIV IFA may use their own IFA based protocols for confirmation of screening test results.

Non-specific IFA results should be clarified whenever possible. The use of absorption will resolve many of these problems and manufacturers are encouraged to develop standard protocols for this and to make cells available for this purpose. Other supplemental tests should be used when absorption cannot resolve the antibody status of a specimen. A positive IFA can be reported as positive, however a negative or a non-specific result should be followed by an additional supplemental test.

The IFA should not be used as a screening procedure.

IFA kit manufacturers are encouraged to submit their products to the FDA for licensure. Public health and other laboratories are encouraged to actively participate in gathering data needed to support these applications.

The following references should be used for Delta Value Calculations:

**Attendees**

Steve Alexander
Tom Armstrong
Dwight Aseltine
Arthur Back
Jeanne Baldwin
J Dean Barry
Vonnia Barton
Lisa Bauman
Carol Bell
Ramon Benet-Ferran
Barry Bennett
Sharon Blumer
Rosemary Boker
Sam Brishett
Sandy Buhler
Kay Buchanan
Tom Callaway
Laurie H Cartwright
Jack Cassorla
Joan C Catignani
Donald C Chambers
Lorraine M Clarke
Carlyn L Collins
Jeanne Connelly
Sandra Currin

Susanne D DesRosiers
P David Dotson Jr
Harold Dowda
Arlette Fauquex
Dennis Ferrero
Bill Fleming
Dana Gallo
Jill Senne Giesick
James A Gibson
Marjorie Giles
Robert K Gleeson
Tim Granade
Samuel B Gregorio
Brigitte Griffith
Louis E Guskey
Richard L Heberling
Sharon Henderson
Theresa L Hodges
Xinyue Hou
Frank R Hunt
Mary Isaac
Jong-Ho Jean
James E Johnson
Farrah Kamalian
J W D Kay

Kim Kelly
Sylvia Kelly
Howard Kim
Warren L Kleinsasser
Jerry Kudlac
Martial LaCroix
Keith Lawrence
Francis Lee
Tsun-Kong Lee
Sadie Lehr
Debbie Lepine
Andrew Levin
Bill Link
James P Lugo
Ron Lynch
Donald Mayo
Patsy McCarty
Lisa T McFarland
Peyton S Metzel
William J Miller
Rick Moody
Phillip P Mortimer
Sherian Newhouse
Nazih Naqwayhid
Debbie Oronzio
<table>
<thead>
<tr>
<th>Name</th>
<th>Name</th>
<th>Name</th>
</tr>
</thead>
<tbody>
<tr>
<td>Percy S Pan</td>
<td>Keith Sayre</td>
<td>Gary Toedter</td>
</tr>
<tr>
<td>Elizabeth Parker</td>
<td>William O Schalla</td>
<td>Darrell Trofimuk</td>
</tr>
<tr>
<td>Theodore E Plucinski</td>
<td>Richard T Schumacher</td>
<td>Richard Walkenbach</td>
</tr>
<tr>
<td>Wolf Prensky</td>
<td>Mark E Schwerzer</td>
<td>Barbara J Weiblen</td>
</tr>
<tr>
<td>Max R Proffit</td>
<td>Luc Segers</td>
<td>Steve Weiss</td>
</tr>
<tr>
<td>Steven Raia</td>
<td>Judy Sheldon</td>
<td>Barbara Werner</td>
</tr>
<tr>
<td>Michael Ramirez</td>
<td>R Ken Shockley</td>
<td>Jane Westerman</td>
</tr>
<tr>
<td>Martha Redus</td>
<td>Mark Sieczkarek</td>
<td>Judith A Wethers</td>
</tr>
<tr>
<td>Marion Reuter</td>
<td>Mel Smith</td>
<td>John A Wilhelm</td>
</tr>
<tr>
<td>Karen L Richards</td>
<td>Catherine Spruill</td>
<td>J Steven Williams</td>
</tr>
<tr>
<td>Donald G Ritter</td>
<td>Richard C Sneece</td>
<td>Jo Ann L Yee</td>
</tr>
<tr>
<td>Bill D Roberts</td>
<td>Susan Stramer</td>
<td>Madonna L Young</td>
</tr>
<tr>
<td>Jane Ruppel</td>
<td>Gary E Tegmeier</td>
<td>Suzanne Zanto</td>
</tr>
</tbody>
</table>

Eleven ASTPHLD laboratories are planning to initiate flow cytometry within the next 12 months. Of the laboratories now performing flow cytometry two routinely test all HIV positives.
RECOMMENDATIONS

2.01 For specimens obtained "on site", with same day processing, EDTA, Heparin, or ACD are suitable. For specimens which are shipped from another site, samples in ACD may be suitable for up to 5 days. For specimens in EDTA or heparin, the maximum transport time is 48 hours.

2.02 Every effort should be made to obtain whole blood samples 24-48 hrs after venipuncture. Samples should be transported at room temperature.

2.03 Dried blood spots appear to be suitable for PCR testing and may be stable for long periods of time. Further data are awaited regarding the sensitivity and specificity of PCR testing from dried blood spots.

2.04 Magnesium concentration must be optimized for each set of primers. Current primers: 1.5-2.5mM

2.05 Annealing and extension conditions must be optimized in each laboratory.

2.06 The number of cycles in the amplification process should be between 30 and 35 for HIV detection.

2.07 Liquid oligonucleotide hybridization (OH) is a highly sensitive and specific detection method and is recommended.

2.08 A variety of non-radioactive detection methods are now available and some have sensitivity and specificity comparable to OH detection. Further comparative testing is recommended.

2.09 In order to obtain the authority to perform and report PCR results, the PCR sub-committee recommends initiation and continuation of discussions with those who hold patents affecting the use of PCR for the purpose of insuring continuation of public health investigations of the diagnosis, etiology, and pathogenesis of diseases of public health importance.

2.10 Laboratories performing PCR should employ a minimum of two primer pairs for initial testing and/or resolution of discrepant results.

2.11 Primers with documented sensitivity and specificity should be used.

2.12 A minimum of two separate PCR reactions (two primer pairs or duplicates of one primer pair) should be performed for each specimen. Splitting of the original specimen is recommended when possible.

2.13 Discrepant results should be resolved by additional analysis of the original specimen using the same or different primer pairs. If discrepant results cannot be resolved by repeat testing, the results should be reported as indeterminate and another specimen should be requested.

2.14 The overall interpretation of PCR testing should be reported as HIV DNA detected, HIV DNA not detected, or Indeterminate.

2.15 Complete testing algorithms need not be reported.
2.16 Appropriate positive, negative, and reagent controls should be included with every PCR test.

2.17 All published guidelines for minimizing the contamination of specimens with amplified PCR product should be rigorously followed.

2.18 Biochemical sterilization of PCR products should be instituted in all PCR laboratories as soon as possible.

2.19 The committee recommends that each laboratory performing PCR conduct validation studies on an appropriate number of well characterized test samples and maintain appropriate records of such test results.

2.20 The development of validation panels for distribution to PCR laboratories by the private sector, NIH, and CDC is recommended.

2.21 The development of standardized reagents and controls in the form of commercial kits is encouraged.

2.22 The immediate initiation of a proficiency testing program for PCR is recommended.

2.23 The application of PCR, in combination with other tests, to the diagnosis of infants born to seropositive mothers is recommended. Additional studies on the use of PCR in the first 3 months of life are needed.

2.24 The use of PCR for retroviral diagnosis in "high risk" seronegative adults is not recommended as a routine procedure.

2.25 The use of PCR for the resolution of indeterminate serology in adults is not recommended as a routine procedure.

2.26 PCR may be helpful in the diagnosis of rare individuals with defective antibody production.

2.27 PCR is useful for the differentiation of viral sub-types (e.g., HTLV-I/II or HIV-1 vs HIV-2).

2.28 The determination of viral burden by PCR may be helpful in the prognosis of HIV disease. However, quantitative PCR requires complex procedures which are not established in most laboratories.

2.29 The use of PCR to monitor the effects of antiviral therapy on viral burden is an important area of future study but has not been validated at this time.

Attendees

Julie Ackerman          Ron Genevie          Gregory Milman
Marion Alleman         G van der Groen       Barry Mitchell
David W Anderson       K Gupta             Patricia Necessary
Connie Ballard         Nancy J Haley        Larry Nelson
Vonita Barton          Cindy Handwerk-Leber   Peter Neumann
R Bauer                W Harry Hannon       E Nichol
Sara T Beatrice        Margaret Hanson      Ken Ostrander
John Boffo             Pat Hays            Gary Oty
Robin Botchlet         Wanda K Jones       Terri Ozegovich
Larry Briggs           Pia Kabin           Jane Rachel
Laurence C Briggs       David Kanatazar     Barry Reed
Nerissa Cabrera        Shyh-Ching Lo      Mike Richey
James M Conroy         Carl Ludvigsen       Pete Rogers
C Darrow               H Craig Lyerla       Becky Rorapaugh
S Delaney              Lisa McFarland       Teresa Salas
Chyang Fang            J Todd McPherson     Carol Schimek
Carol Ferrera          Bruce McCreedy       Nick Schmitz
Bagher Forghani        Jim Mahony          G Schochetman
Fritz Friedhoff        Dave Marshman        Caterina Sellitto
Myriam Garcia          Jeff Massey         M Steller
Pat Garrett            Frank J Michalski    Roy Stevens

Sixth Annual Conference on Human Retrovirus Testing  15
Thirty nine (75%) of ASTPHLD laboratories participated in the CDC Family of Serosurveys during FY90.
FLOW CYTOMETRY
PANEL SESSION 3

ROOM: EMPIRE C
TIME: 8:30 TO 10:00 AND 10:45 TO 12:00, WEDNESDAY, MARCH 6, 1991
CHAIR: Jonathan M Kagan, Ph.D., Chief, Clinical Sciences Section, Treatment Research Program, Division of Acquired Immunodeficiency Syndrome (AIDS), National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland
MEMBERS: Russell Gerber, M.D., Center for Infectious Diseases, Centers for Disease Control, Atlanta, Georgia; Janet K A Nicholson, Ph.D. Center for Infectious Diseases, Centers for Disease Control, Atlanta, Georgia (Rapporteur);
TOPICS: Quality assurance; Training; Monitoring antiviral therapy; Reporting criteria and interpretation; Disease staging

RECOMMENDATIONS

3.01 Each public health laboratory should evaluate the need to establish flow cytometry capability based on an assessment of criteria including: prevalence of HIV infection and cumulative incidence of AIDS within the area served, ability to monitor and evaluate the quality of flow cytometry and pertinent hematology results, cost effectiveness, and the availability of other early HIV intervention services. Additional data are needed before specific recommendations can be made on non-retroviral public health and environmental applications of flow cytometry.

3.02 Flow cytometry training should be mandatory for all relevant personnel including instrument operators, laboratory supervisors and laboratory directors.
   (a) All instrument operators should, in addition to flow cytometer manufacturer’s training, receive supplementary training through additional courses or workshops offered by independent organizations. In-house training at experienced laboratories may be an acceptable alternative.
   (b) Clinical flow cytometry training courses for laboratory directors and supervisors should be developed.
   (c) The ASTPHLD recommends the development of certification programs for laboratory technicians trained in flow cytometry.
   (d) The ASTPHLD recommends the development and implementation of accreditation standards for all training courses and workshops in clinical flow cytometry.

3.03 The ASTPHLD should assemble and make available updated information on clinical flow cytometry training courses and workshops.

3.04 Before accepting specimens for clinical flow cytometric analysis, each laboratory must have in place a comprehensive quality assurance protocol that includes standardization, quality control procedures, and proficiency testing.
   (a) Standardization of instrument optical alignment, spectral sensitivity, and fluorescence compensation must be performed daily.
   (b) Quality control includes daily monitoring and recording of instrument performance and cell preparation methodologies. Reagent stability should be assessed with lot changes and as otherwise needed.
   (c) Proficiency testing within a nationally recognized program on a quarterly basis is required as an integral component of comprehensive quality assurance.

3.06 The determination of absolute counts for lymphocyte subsets requires both hematologic and flow cytometric measures.

For hematologic measures:

(a) Determination of the absolute lymphocyte count requires both a white blood cell count (WBC) and a differential (including percent lymphocytes). The ASTPHLD endorses the NCCLS Tentative Standard (1984), H-20T, Leukocyte Differential Counting. The optimal specimen for these hematologic measures is EDTA-preserved whole blood (lavender top tube) less than six hours old.

(b) Recognizing that laboratories may receive hematologic specimens more than 6 hours old, the ASTPHLD recommends consideration of the following options:

(1) Hematologic analysis may be performed within six hours locally and a second specimen (drawn simultaneously) for flow cytometry may be transported to the flow cytometry laboratory. It may be desirable to obtain a fresh smear for quality assurance.

(2) Laboratories can verify the maximum age of specimens for which hematologic results are comparable to fresh specimens.

(c) The laboratory performing the hematology should maintain a documented intralaboratory coefficient of variation less than five percent for the white blood cell (WBC) count.

(d) Laboratories should evaluate and characterize intralaboratory bias and establish confidence intervals for the WBC and the differential lymphocyte counts.

(e) Automated differentials are strongly recommended. Manual differentials should count at least 400 cells.

For flow cytometric measures:

(a) The optimal specimen for lymphocyte immunophenotyping by flow cytometry is either an EDTA-preserved whole blood specimen less than six hours old or an heparinized whole blood specimen up to 24 hours old.

(b) Recognizing that laboratories may receive suboptimal (old) flow cytometric specimens, ASTPHLD recommends that laboratories verify the maximum age of specimens for which immunophenotyping results are comparable to fresh specimens.

(c) Optimally, specimens should be maintained at room temperature (18-22°C) until tested.

3.07 Whole blood lysis and two-color immunofluorescence are the methods of choice for flow cytometric immunophenotyping.

3.08 The ASTPHLD recommends the following two-color monoclonal antibody panel for routine immunophenotyping:

<table>
<thead>
<tr>
<th>Monoclonal Antibody Combination</th>
<th>Cell Type Enumerated</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. IgG_1/IgG_2</td>
<td>Isotype controls</td>
</tr>
<tr>
<td>2. CD45/CD14</td>
<td>% lymphocytes in gating region</td>
</tr>
<tr>
<td>3. CD3/CD4</td>
<td>T-helper/inducer subset</td>
</tr>
<tr>
<td>4. CD3/CD8</td>
<td>T-suppressor/cytotoxic subset</td>
</tr>
<tr>
<td>5. CD3/CD16 + CD56</td>
<td>Total T cells/Total NK cells</td>
</tr>
<tr>
<td>6. CD19</td>
<td>Total B-Cells</td>
</tr>
</tbody>
</table>

* FITC/PE-labeled reagents

b Lymphocytes will be CD45 bright CD14 negative

c Indicated cell type will be positive for both antibodies

d Total T cells = all cells expressing CD3; Total NK cells = all cells which are CD3 negative but positive for CD16 and/or CD56.
3.09 Lymphocyte light scatter gates must be validated by anti-CD45 (pan-leukocyte) and anti-CD14 (monocyte) reactivity.

(a) Optimally, non-lymphocyte contamination within the gate should not exceed 5 percent. 85% is the lower limit of acceptable lymphocyte representation in the lymphocyte gate.

(b) At least 95 percent of lymphocytes should be contained within the light scatter gate.

3.10 Lymphocyte subset percentage values from the flow cytometer should be corrected by dividing the observed percentage by the percentage of lymphocytes (CD45$^{high}$CD14$^{neg}$) in the lymphocyte gating region.

3.11 For most specimens, the total of the corrected CD3$^{positive}$ (Total T), CD19$^{positive}$ (Total B), and CD3$^{negative}$CD56$^{positive}$ &/or CD16$^{positive}$ (Total NK) percentages should sum to between 95 and 105 percent.

3.12 Each laboratory must establish age- and population-appropriate reference ranges in accordance with validated statistical criteria. It should be noted that pediatric reference ranges may differ substantially from the reference ranges for adult populations.

3.13 The manufacturers of flow cytometry instrumentation and reagents are urged to cooperatively expedite the development of:

(a) Improved lymphocyte gating reagents

(b) Automated sample preparation technology

(c) Flow cytometers capable of determining absolute numbers for lymphocyte subsets

(d) Improved laboratory quality control reagents

(e) Anticoagulants and preservatives suitable for both hematologic and flow cytometric measurements

3.14 Laboratory reports should optimally include lymphocyte subset percentages, absolute values and laboratory reference ranges.

(a) Laboratory reports should specify the immunophenotype (CD designation) for all lymphocyte subsets reported therein (e.g., T-helper/inducer = CD3$^{positive}$/CD4$^{positive}$).

(b) Values for lymphocyte subsets should be corrected for the lymphocyte representation in the gating region.

(c) Absolute values for lymphocyte subsets should be reported unless hematologic results are suspect.

3.15 The ASTPHLD strongly supports efforts by the Centers for Disease Control to establish a national lymphocyte immunophenotyping performance evaluation program including training and education programs.

3.16 The ASTPHLD strongly supports the efforts of the NCCLS and the NIAID Flow Cytometry Advisory Committee in setting standards for clinical flow cytometric immunophenotyping.

3.17 The ASTPHLD encourages the development of alternative (non flow cytometric) methods for the enumeration of CD4 lymphocytes.


**Attendees**

Greg Ballish  
Mark Connelly  
G David Cross  
Giacobino DeChirico  
Kenneth P Dressler  
Margaria Garcia  
Jane Getchell  
George F Grady  
Sherry Harris  
Gerald L Hoff  
Timn Hurst  
Monica Krieger  
Robert Lindner  
Kathleen Meckstroth  
James L Pearson  
Michael Peddedcord  
Mary Richardson  
William Slanta  
Ann Toledo  
Wallis M Velleca  
John G Warhol

---

*Sixth Annual Conference on Human Retrovirus Testing*
ROOM: EMPIRE A/B
TIME: 1:30 TO 3:00, WEDNESDAY, MARCH 6, 1991
CHAIR: Chyang Fang, Ph.D., Director, National Reference Laboratory for Infectious Diseases, American Red Cross, Rockville, Maryland
MEMBERS: J Richard George, Ph.D., Chief, Developmental Technology Section, Centers for Disease Control, Atlanta, Georgia; Jonathan Kaplan, M.D., Retrovirus Diseases Branch, Centers for Disease Control, Atlanta, Georgia; Helen Lee, Ph.D., Director, Transfusion Biology Research and Development, Abbott Laboratories, North Chicago, Illinois (Rapporveur); Roy Stevens, Ph.D., Director of Laboratories for Diagnostic Immunology, New York State Department of Health, Albany, New York; Barbara Werner, Ph.D., Director, Clinical Investigation and Virology, State Laboratory Institute, Boston Massachusetts
TOPICS: HTLV-I and HTLV-II differentiation; Confirmation methodology and criteria for HIV-1/HIV-2 and HTLV-I/II; HIV-1/HIV-2 combination tests; Rapid testing methods

RECOMMENDATIONS

4.01 We encourage manufacturers to develop second generation confirmatory tests to replace the current WB/RIPA procedures with assays utilizing recombinant proteins and/or synthetic peptides in formats that allow objective reading.
4.02 The inclusion of p19 + gp46/61 pattern as confirmatory for HTLV-I/II seropositivity should be further evaluated.
4.03 The utility of p21 in the current confirmation criteria needs to be validated; the specificity of recombinant p21 in particular, should be further evaluated.
4.04 Since HTLV-I and HTLV-II infections have different disease manifestations, we recommend that public health laboratories carry out, if possible, routine differentiation of HTLV-I from HTLV-II in HTLV-I/II seropositive samples.
4.05 We encourage the development and evaluation of recombinant and/or synthetic peptide reagents for the differentiation of HTLV-I from HTLV-II antibodies.
4.06 We recognize that current HTLV-I screening assays will occasionally fail to detect HTLV-II antibodies and encourage systematic epidemiological and laboratory studies to determine the sensitivity of HTLV-I reagents for HTLV-II antibody detection. If a sizeable percentage of HTLV-II antibodies are missed, the development of a more sensitive second generation HTLV assay is recommended.
4.07 National surveillance for HIV-2 infections should be continued.
4.08 HIV-1 seronegative or indeterminate persons with AIDS related symptoms or those at risk for HIV-2 infection should be considered as candidates for HIV-2 antibody testing.
4.09 Upon the availability of HIV-1/2 combination tests, the public health laboratories should consider the importance of adopting the combination assays based on epidemiological data pertinent to the local area.
4.10 The ASTPHLD Committee On Human Retrovirus Testing should appoint a committee composed of representatives from public health laboratories and manufacturers to determine the characteristics of standard HIV-2 confirmatory tests. For example, for Western blot, these would include the virus strain, purification and processing of antigens, and interpretive criteria.
<table>
<thead>
<tr>
<th>Attendees</th>
<th>Attendees</th>
<th>Attendees</th>
</tr>
</thead>
<tbody>
<tr>
<td>Julie Ackerman</td>
<td>Tim Granade</td>
<td>Max R Proffitt</td>
</tr>
<tr>
<td>Steve Alexander</td>
<td>Guido van der Groen</td>
<td>Jane Rachel</td>
</tr>
<tr>
<td>David Anderson</td>
<td>K Gupta</td>
<td>Steven Raia</td>
</tr>
<tr>
<td>Tom Armstrong</td>
<td>Nancy J Haley</td>
<td>Barry Reed</td>
</tr>
<tr>
<td>Arthur Back</td>
<td>Cindy Handwerk-Leber</td>
<td>Karen L Richards</td>
</tr>
<tr>
<td>Connie Ballard</td>
<td>Sherry Harris</td>
<td>Mary Richardson</td>
</tr>
<tr>
<td>Vonnita Barton</td>
<td>Sharon Henderson</td>
<td>Donald Ritter</td>
</tr>
<tr>
<td>R Bauer</td>
<td>Frank R Hunt</td>
<td>Becky Rorapaugh</td>
</tr>
<tr>
<td>Lisa Bauman</td>
<td>Jong-Ho Jean</td>
<td>Jane Ruppel</td>
</tr>
<tr>
<td>James Beebe</td>
<td>James E Johnson</td>
<td>Keith Sayre</td>
</tr>
<tr>
<td>Sharon Blumer</td>
<td>Stephen Josephson</td>
<td>Nick Schmitz</td>
</tr>
<tr>
<td>John Bofo</td>
<td>Farrah Kamalian</td>
<td>Richard T Schumacher</td>
</tr>
<tr>
<td>Rosemary Boker</td>
<td>J W D Kay</td>
<td>Luc Segers</td>
</tr>
<tr>
<td>Kay Buchanan</td>
<td>Kim Kelly</td>
<td>Caterina Sellitto</td>
</tr>
<tr>
<td>Nerissa Cabrera</td>
<td>Sylvia Kelly</td>
<td>Judy Sheldon</td>
</tr>
<tr>
<td>Laurie H Cartwright</td>
<td>Howard Kim</td>
<td>Catherine Spruill</td>
</tr>
<tr>
<td>Jack Cassoria</td>
<td>Monica Krieger</td>
<td>Richard C Steece</td>
</tr>
<tr>
<td>Lorraine M Clarke</td>
<td>Martial LaCroix</td>
<td>M Steiler</td>
</tr>
<tr>
<td>Cindy Collins</td>
<td>Tsun-Kong Lee</td>
<td>Susan Stringer</td>
</tr>
<tr>
<td>Jeanne Connelly</td>
<td>Debbie Lepine</td>
<td>Steve Stump</td>
</tr>
<tr>
<td>Cynthia Cassen</td>
<td>James P Lugo</td>
<td>Gary E Tegmeier</td>
</tr>
<tr>
<td>Steve Dahlan</td>
<td>Bruce McCreedy</td>
<td>Ann Toldo</td>
</tr>
<tr>
<td>Clem Darrow</td>
<td>Peyton S Metzel</td>
<td>Darrell Trifmuk</td>
</tr>
<tr>
<td>P David Dotson Jr</td>
<td>Patricia Necessary</td>
<td>John Vernasco</td>
</tr>
<tr>
<td>Kenneth Dressler</td>
<td>Larry Nelson</td>
<td>Michael Wandall</td>
</tr>
<tr>
<td>Arlette Fauquex</td>
<td>Richard H Newhouse</td>
<td>John Warhol</td>
</tr>
<tr>
<td>Carol Ferrera</td>
<td>Nazira Nuwayhid</td>
<td>Stephanie Wells</td>
</tr>
<tr>
<td>Bill Fleming</td>
<td>Debbie Oronzio</td>
<td>Jane Westerman</td>
</tr>
<tr>
<td>Dana Gallo</td>
<td>Ken Ostrander</td>
<td>John A Wilhelm</td>
</tr>
<tr>
<td>Jill Giesick</td>
<td>Gary Ory</td>
<td>J Stephen Williams</td>
</tr>
<tr>
<td>James A Gibson</td>
<td>Terri Ozegovich</td>
<td>Dave Wyllie</td>
</tr>
<tr>
<td>Marjorie Giles</td>
<td>Percy S Pan</td>
<td>Jo Ann L Yee</td>
</tr>
<tr>
<td>Robert K Gleeson</td>
<td>Elizabeth Parker</td>
<td>Madonna L Young</td>
</tr>
</tbody>
</table>

* Ninety two percent of the ASTPHLD laboratories follow the recommendations of ASTPHLD-CDC in performing and interpreting the Western Blot.*
The committee recommends the continuation of prospective studies for evaluation of relevant tests for the early diagnosis of infection especially to identify rapid progressors. Prospective studies should include comparison analysis of PCR, culture, Elispot and HIV specific IgA antibodies.

5.02 PCR appears to be the most sensitive test for diagnosis of HIV infection in the first three months of life.

5.03 Negative results obtained on specimens from infants less than one month of age must be regarded as tentative. Additional specimens should be tested from these infants at ages greater than one month. Positive results obtained within the first month of life must be confirmed with tests on an independent specimen as soon as possible (preferably in the first two months of life). All positive PCR results regardless of age should be confirmed with tests on an independent specimen.

5.04 Virus culture is an effective tool for diagnosis of HIV infection in young children. A negative result does not rule out infection; a positive result should be confirmed.

5.05 ELISPOT is a promising new test for the diagnosis of infection in infants in the first 3 months of life. It may complement PCR testing during the neonatal period. The committee recommends further testing on early specimens to evaluate its predictive value.

5.06 IgA HIV antibody tests are of limited diagnostic value in neonates but may be positive by three months of age. Because the IgA test is a simple modification of existing technology, it may be useful as a supplemental test in regional laboratories.
Michigan is the only state to require prenatal HIV testing.
STANDARDS OF PRACTICE
PANEL SESSION 6

ROOM: EMPIRE C
TIME: 1:30 TO 3:00, WEDNESDAY, MARCH 6, 1991
CHAIR: Dale Lawrence, M.D., Chief, Clinical Development Section, Vaccine Research and Development Branch, Basic Research and Development Program, Division of AIDS, National Institute of Allergy and Infectious Diseases, Rockville, Maryland
MEMBERS: Susan Mottice, Ph.D., Director, Microbiology, Utah State Health Department, Salt Lake City, Utah; Lt. Col. Chester Roberts, Ph.D., Chief, Diagnostic Retrovirology, Walter Reed Army Institute of Research, Rockville, Maryland; Judith Wethers, M.S., Director, Testing Services, Retrovirology Laboratory, State of New York Department of Health Laboratories, Albany, New York
RAPPORTEUR: Keith Lawrence, Administrator, New York City Department of Health, New York, New York
TOPICS: Reporting; Testing of vaccinated individuals

RECOMMENDATIONS

6.01 This workshop reaffirms the reporting procedures recommended by the 5th Consensus Conference, with the addition by reference to Section 9.02.f.Item2:
"A narrative laboratory interpretation, including a reference to immune response elicited by vaccines."

6.02 We welcome the drafting by CAP of anti-HIV test reporting guidelines and encourage all ASTPHLD attendees to review and provide feedback to CAP.

6.03 Persons interpreting Western blot tests should be aware that participation by initially seronegative volunteers in clinical trials of HIV/AIDS vaccines will likely result in the acquisition of detectable immune responses to HIV. These responses may include the development of a positive ELISA test and Western blot bands reflecting the antigenic formulation and immunogenicity of the vaccine. Some vaccines may induce Western blot bands which meet published criteria for a positive test.

6.04 During succeeding years, the testing of various types of vaccine formulations can be anticipated. To preclude misclassification of a vaccinated volunteer with a positive HIV antibody test result as infected, it will be necessary that interpretation take into account the past HIV vaccine immunization history.
To assist in this, the following procedures should be implemented by HIV/AIDS vaccine investigators:
a: At the conclusion of a trial, volunteers should be provided with information on the vaccine formulation(s) administered along with, as a minimum, the results of their ELISA and Western blot tests post-vaccination.
b: Participants should have long-term accessibility to this information with safeguards to protect confidentiality.

6.05 The NIH is supported in its effort to develop for publication, in concert with the CDC and other relevant agencies, an MMWR advisory acknowledging the unique circumstances surrounding HIV/AIDS vaccine study participation.
Attendees

Marian Alleman  Margaret Hanson  Sherian Nestor
Carol Bell  Theresa L Hodges  James Pearson
Barry Bennett  Gerald Hoff  Michael Peddicord
Robin Botchlet  Xinyue Hou  Theodore E Plucinski
Carlton L Collins  Timm Hurst  Wolf Prensky
G David Cross  Mary Isaac  Ken Schockley
Susanne D DesRosiers  David Kantazar  Mark Sieczkarek
Dennis Ferrero  Warren L Kleinsasser  Mel Smith
Fritz Friedhoff  Sadie Lehr  Henry Strother
Myriam Garcia  Bill Link  Roger Taylor
Pat Garrett  Carl Ludvigsen  Wallis M Velleca
A Russell Gerber  H Craig Lyerla  Jeffery S Webb
Bob Gleeson  Ron Lynch  Judith A Wethers
Samuel B Gregorio  Kathleen Meckstroth  Judith Wilber
Brigitte Griffith  Rick Moody  Suzanne Zanto

Twenty eight percent of ASTPHLD laboratories routinely request a second sample to confirm a positive test result.
POSTER PRESENTATIONS

(The presenter is listed in bold print.)

1  **J E Johnson**
   Comparison of Whole Cell Viral Lysate (VL), Synthetic Peptide (SP), and Recombinant Protein (RCP) EIA's for Detection of HIV-1 Antibody

2  **J P Montana, L Gosting, C A Cole, N Monji, P Su, P F Coleman**
   Detection of Antibodies to HIV-1 and HIV-2 by a Single, Rapid Peptide-Based Immunoassay

3  **C Ferera, N Dock, J Huprikar, J Phair, M Kreiger**
   Use of a Peptide-Based, Rapid Immunoassay for Antibody to HIV-1 to Clarify True Antibody Status of EIA Repeat Reactive, Western Blot Indeterminates

4  **W Link**
   Effect of Non-Specific Glycoprotein Bands on Interpretation of HIV-1 Western Blots

5  **Brigitte P Griffith, Thomas M Chacko**
   Comparative Performance of Peptide, Recombinant and Viral Lysate Based Enzyme Immunosorbent Assays for the Detection of HIV-1 Antibody

6  **Emerson W Chan, Werner Schulze, Michael Leuther, Kevin Knigge**
   Monitoring IgG, IgA, and IgM Responses to HIV-1/HIV-2 Infections by Modified Abbott Matrix Assays

7  **Susan Pederson, L J Croy, L Adams, S Cobel, C Ferrera, M Krieger, K Shriver**
   Development of an Enzyme Immunoassay for Simultaneous Detection of Antibodies to HIV-1 and HIV-2

8  **K Richards**
   Performance of the Microtrak HIV-1 (env & gag) Recombinant Antigen Enzyme Immunoassay - Summary of Field Trial Data

9  **Barbara G Werner, Charles Schable, Monica Krieger**
   HIV-2 Infection in a Patient Screened HIV-1 Negative

10 **J Gregg, C Ludvigsen, B Roberts**
    Detection of Antibodies Directed to HIV-1 in Oral Mucosal Transudate

11 **Cynthia K Cossen, Shirley J Hagens, Michael Ascher, M. D., Patricia Stewart, Monica Krieger, Ph.D.**
    Use of a HIV-1/HIV-2 Combination EIA Test with Dried Blood Spot Samples

12 **Cynthia K Cossen, Shirley J Hagens, Michael Ascher, M. D.**
    A Comparison of Three HIV-1 Western Blot Methods

13 **B Forghani, J Hurst, C Chan**
    Study of Nonspecific Immunofluorescence of Repeat EIA HIV-1 Reactive Sera using HIV-1 Persistently Infected HeLa T4+ Cells
14 C Starkey, B Yen-Lieberman, M Proffitt
Evaluation of the Cambridge BioScience Recombigen HIV-1 EIA as a Supplementary Test for Detection of Antibodies to Human Immunodeficiency Virus Type I

15 M Proffitt, C Starkey, B Yen-Lieberman, D Hatch, S Schindler
Serum HIV p24 Antigen Testing of Individuals at Risk of Having Been Infected with HIV-1

16 M T Ramirez, N S Swack, W J Hausler, Jr
Reactivity of 6 Commercial HIV-1 EIA Test Procedures on Western Blot Indeterminate Sera

17 Martha A Redus, Shari Wasser, W Harry Hannon, J Richard George, Marta Gwinn, George F Grady, Lynne M Mofenson
Estimates from the National HIV Survey in Childbearing Women

18 Joseph S Niedbalski, Steven J Dahlen, Brian P Braun
Matrix HIV-1/HIV-II: a New Alternative to the Western Blot

19 J H Jean, S Dee, D Phillips, K Hurley, M P Verma, J C Ridderhof
Evaluation of Microtrak HIV-1 EIA (env & gag) Test with Selected Specimens

20 Richard T Schumacher, J Howard, L Ayres, A Pista, F Avillez, P Garrett
Cross-Reactivity of Anti-HIV-2 Positive Specimens in FDA Licensed Screening Tests for Anti-HIV-1

21 G David Cross, W O Schalla, S O Blumer, J S Hancock, R N Taylor, A R Gerber, T L Hearn
Inter-Shipment Reproducibility of Laboratories Participating in a Performance Evaluation Program

22 Susan L Stramer, Cheryl J Mitten, Mary B Mathieu, Jeannie L Schneut, Xiomara Alcade, Jean Pierre Allain, Charles Schable, Richard Schumacher
A Combination Anti-HIV-1/HIV-2 EIA Using Both Viral and Recombinant Antigens

23 J A Connell, J V Parry, P P Mortimer
IgG Antibody Capture Elisa A Diagnostic Test for Anti-HIV Applicable to All Body Fluids

24 J A Connell, J V Parry, P P Mortimer
GACPAT: A Tool for Unlinked Testing of Urine Specimens

What do Human T-Lymphocyte Immunophenotyping Reports Contain? Results of a Case-Series

26 E Oluoch, Susan Pederson, J Schwebke, K Holmes, J Kleyn, D A Caslyn, A J Saxon, S Whittaker, L Olmsted, R Masinovsky, K Shriver
PCR Analysis of Intravenous Drug User Samples Reactive with HTLV-I and HTLV-II

27 Anne M Comeau, Barbara Weiblen, Jo-Ann Harris, Ken McIntosh, Rod Hoff
Analysis of Early Infant Specimens by the Polymerase Chain Reaction (PCR) for the Detection of HIV-1 Proviral DNA

28 Anne M Comeau, Galina Mushinsky, Karl Adler
Analysis of PCR Sensitivity Using DuPont HIV-1 Pol Repliprimers and DNA Titerplate Hybridization System

29 J Ackerman, W Link
Effect of Including gp21 in Interpretation Criteria for HTLV-1 Western Blot
30 H F Polesky, M Hanson
Practice Guidelines for Reporting HIV Test Results

31 Mark E Schwerzler, Barbara Weiblen, Barbara Werner, Monica Krieger, George F Grady
HIV-2 Infection in Child-bearing Women Detected by Newborn Screening

32 M Dobec, J A Wilhelm, R Baumgartner, M Jung
Differentiation of HTLV-I and II Infections using IFA

33 Barbara Weiblen, Anne Comeau
Early Diagnosis of HIV Infection in Infants by Detection of IgA and IgM HIV Antibodies

34 Sharon O Blumer, William O Schalla, G David Cross, John S Hancock, Roger N Taylor, A Russell Gerber, Thomas L Hearn
Evaluation of the Performance of Laboratories that Test for Human T-Lymphotropic Virus Antibodies

35 A Russell Gerber, G David Cross, William O Schalla, John S Hancock, Sharon O Blumer, Thomas L Hearn
Evaluation of Laboratory Performance of T-Lymphocyte Immunophenotyping in Support of Early HIV-1 Intervention and Prevention

36 Dana Gallo, Peter J Dailey, Carl V Hanson
Antigenicity of New HTLV-II-Infected Cell Lines Derived from California IVDU

37 T C Granade, B Parekh, S Phillips, C-P Pau, M Redus, M Gwinn, J R George
Characterization of the Western Blot Testing Methods for Detecting Antibodies to HIV-1 in Elutes of Dried Blood Collected on Filter Paper

38 John W D Kay, Andrew Goldstein (Detection in Urine)
John W D Kay, Thomas H Grove (Detection in Saliva)
Adaptation of a Serum/Plasma/Dried Blood Spot Licensed High Performance ELISA System for Detection of HIV-1 Antibodies in Saliva and Urine
Evaluation of enzyme-linked immunosorbent assays: a method of data analysis

Nick Crofts, William Maskill and Ian D. Gust
National HIV Reference Laboratory, Fairfield Hospital, Fairfield Victoria, Australia
(Accepted 12 April 1988)

Summary

Diagnostic tests are usually evaluated in terms of simple qualitative measures of sensitivity and specificity. When comparing different quantitative assays such as ELISAs, it is often more useful to deal with actual values (sample optical density/cut-off optical density ratio (OD ratio)) rather than the qualitative relationship to the cut-off, i.e. positive or negative. This allows for a statistical approach to the questions of sensitivity and specificity. The National HIV Reference Laboratory of Australia has developed an approach for determining statistical estimates of sensitivity and specificity in terms of delta (δ). Delta is defined as the distance of the mean OD ratio of the sample population from the cut-off measured in standard deviation units. This paper discusses the derivation of this measurement and its usefulness when evaluating ELISA tests.

ELISA; Evaluation; Diagnostic test: Delta

Introduction

In Australia, the responsibility for evaluating diagnostic tests for HIV infection falls upon the National Reference Laboratory (NRL) located at Fairfield Hospital, Melbourne. In the course of evaluating a number of enzyme linked immunosorbent assays (ELISA) it became clear that methods of comparison, traditional in the field of serology, were unable to reliably distinguish tests of high specificity and sensitivity, and that new methods of analysis were required.

Correspondence to: Dr. W.J. Maskill, National HIV Reference Laboratory, Fairfield Hospital, P.O. Box 65, Fairfield, Victoria 3078, Australia.
Evaluation of enzyme-linked immunosorbent assays: a method of data analysis

Nick Crofts, William Maskill and Ian D. Gust

*National HIV Reference Laboratory, Fairfield Hospital, Fairfield Victoria, Australia*

(Accepted 12 April 1988)

Summary

Diagnostic tests are usually evaluated in terms of simple qualitative measures of sensitivity and specificity. When comparing different quantitative assays such as ELISAs, it is often more useful to deal with actual values (sample optical density/cut-off optical density ratio (OD ratio)) rather than the qualitative relationship to the cut-off, i.e. positive or negative. This allows for a statistical approach to the questions of sensitivity and specificity. The National HIV Reference Laboratory of Australia has developed an approach for determining statistical estimates of sensitivity and specificity in terms of delta (δ). Delta is defined as the distance of the mean OD ratio of the sample population from the cut-off measured in standard deviation units. This paper discusses the derivation of this measurement and its usefulness when evaluating ELISA tests.

**ELISA: Evaluation; Diagnostic test: Delta**

Introduction

In Australia, the responsibility for evaluating diagnostic tests for HIV infection falls upon the National Reference Laboratory (NRL) located at Fairfield Hospital, Melbourne. In the course of evaluating a number of enzyme linked immunosorbent assays (ELISA) it became clear that methods of comparison, traditional in the field of serology, were unable to reliably distinguish tests of high specificity and sensitivity, and that new methods of analysis were required.

Correspondence to: Dr. W.J. Maskill, National HIV Reference Laboratory, Fairfield Hospital, P.O. Box 65, Fairfield, Victoria 3078, Australia.
The two most common problems encountered with evaluations of ELISA tests are failure to consider the effects of sample size, and the selection of a sample that is unrepresentative of the population in which the test is to be used.

Failure to consider the effects of sample size has greatest effect when attempting to rank or distinguish between tests of high sensitivity and specificity. When considering sampling error and the confidence limits for the sensitivities and specificities, there often is no statistically significant difference between the estimates obtained for the different tests being evaluated due to an inadequate sample size. For example, to distinguish between tests having specificities which differ by 0.1% with any degree of statistical confidence, more than 15,000 specimens would need to be tested. In addition, information is lost when analysing data from evaluations in a qualitative manner since the individual readings for each sample are ignored by treating all positive (and negative) results as equivalent. The answers to important questions when evaluating ELISA assays can only be obtained by analysing actual test values. For example, do the false positive samples have readings close to the cut-off? If they do, and if the test shows a clear separation of the readings for the antibody positive and negative samples then the problem with the test is simply to do with the position of the cut-off; if it were to be slightly adjusted, the test might appear extremely good. Alternatively, do the false positive readings lie in an area where most of the positive results also lie? If this is the case, the test is fundamentally flawed. A method of analysing the effect of different settings of the cut-off is the Receiver Operating Characteristic (ROC) curve which has been applied in many settings (Swets and Pickett, 1982; Lusted, 1971).

Alternative approaches

To establish how a quantitative assay performs on a particular sample of specimens, or to compare different assays on one sample of specimens, it is more useful to deal with actual values than their qualitative relationship to the cut-off. This allows a statistical analysis of test efficacy which uses all information produced by an evaluation.

The statistical approach, which has been used by some workers (Weiss et al., 1985), is often marred by the assumption that the results are normally distributed. This assumption often underlies methods of calculation of the cut-off for a particular test, for example, the mean of the negatives plus three standard deviations. If the distribution of results is non-normal, this approach can give very misleading results. The ELISA methodology gives a sigmoidal response curve when optical density is plotted against concentration of antibody. When this test method is applied to a population in which antibody concentrations are normally distributed, the resulting curves tend to be log normal. If appropriate transformations are not performed before summary analysis, results can be misleading.

It would, however, be useful to have a method of analysing quantitative diagnostic tests which can be easily summarized in meaningful parameters. The ROC curve fulfils these criteria (Staquet et al., 1980), but does not immediately demonstrate important relationships to the non-statistician. Here we outline an approach developed at the NRL, for evaluations of anti-HIV screening tests.
Approach developed at the NRL

Most evaluations have consisted of testing panels of specimens 'known' (on the basis of information derived from a variety of clinical and serological sources) to be positive for antibody to HIV, obtained from subjects with as wide a spectrum of disease and from as diverse epidemiological groups as possible; and of specimens 'known' to be negative for anti-HIV, again from as representative a sample as possible.

When these panels are tested by indirect ELISA, and the frequency of results of a particular reading are plotted against that reading, curves of the general shape shown in Fig. 1A are obtained. In fact, each represents a family of curves, because a different curve is generated for each test run; there is a shift to left or right along the x-axis, due to variation in the cut-off value which varies from run to run. The distribution of positive results should extend far to the right of the graph (Fig. 1A, -A-) but because there is often an upper limit to the readings obtainable with ELISA readers, it may be compressed to the left (Fig. 1A, ++-). Plotting the variation (shift) between runs is a useful quality control device, but for evaluating tests it is more satisfactory to standardise each reading by assigning the cut-off an ar-

Fig. 1. Diagrammatic representations of curves obtained by plotting values produced by testing by ELISA populations of known negatives (O-) and known positives (-A-): A, B and C as percentages, D as cumulative percentages: a = false positive rate, b = false negative rate. The expected OD values for positive samples (-A-). Compressed OD values for positive samples obtained from ELISA readers (++-) (see text).
arbitrary value of 1, and plotting each reading in relation to this value. When this is done all the curves can then be treated as one population. This standardisation is normally performed by dividing each reading by the cut-off; this produces an OD ratio for each sample tested.

Comparisons between curves can then be made. Plotting frequency of results against ratio produces curves with similar shapes as previously, but standardised against the same reference point (Fig. 1B).

Two problems remain with these standardised curves: firstly, it is often difficult to fit positive and negative results on the same graph (because the spread of positives is so much greater than that of the negatives) and secondly the curves are generally log normal or approximately log normal. The simple answer to both problems is to change the ratio from a linear to a logarithmic scale (Fig. 1C); this brings the two distributions onto one graph and 'normalises' most of the curves (i.e. they become symmetrical about their means), so that they can be described satisfactorily by their mean $X$ and standard deviation ($S$).

Fig. 2. Separation of negative and positive test populations using mean criteria only. Representation of curves obtained by testing populations of known negatives (-□-) and known positives (-▲-) by two different ELISAs, A and B: $X_{A-} = \text{mean of negatives for kit A}; X_{A+} = \text{mean of positives for kit A}; X_{B-} = \text{mean of negatives for kit B}; X_{B+} = \text{mean of positives for kit B}; d_A = \text{distance between means for kit A}; d_B = \text{distance between means for kit B}.$
The same data can also be presented as cumulative percentages (Fig. 1D). Both these latter approaches (Fig. 1C, D) demonstrate clearly how effectively the test separates the positive and negative populations, and illustrate the percentage of false positive (a) and false negative (b) results which can be expected.

It would be convenient to have a single measure which summarises how effective a test is at separating positive and negative populations so that different tests could be rated by a single figure. One such measure might be the difference between the means of the positive and negative populations on the assumption that the greater the difference, the better the kit is at separating the two populations. This measure is not reliable as it fails to take into account differences in the distribution of results which may be obtained with different tests as shown in Fig. 2. In this example both kits produce the same value for the difference between the means of the antibody positive and negative populations; however, kit B is obviously the better test as there is no overlap of the two populations.

A measure which takes into account the spread of results as well as the distance between means, is the 'index of detectability' (d') (Lusted, 1971); this is denoted by Armitage as 'Delta' (\(\Delta\)) (Armitage, 1971).

This measure requires two assumptions; that the distributions are normal and that the variances of the two distributions are approximately equal. While the first assumption is met when ELISA generated curves are log transformed, the second is rarely met.

Because of this we are forced to use two measures – one for the positives and one for the negatives – to describe the efficacy of the test fully. These measures we call 'delta' (\(\delta\)) measures; they are defined as the distance of the mean of the distribution from the cut-off in standard deviation units (Fig. 3). Thus delta for the

---

**Fig. 3.** Separation of negative and positive test populations using mean and standard deviation criteria. Representation of distributions of log OD ratios obtained by testing populations of known negatives (- - -) and known positives (- - -). \(\bar{X}_n\) = mean of negatives; \(\bar{X}_p\) = mean of positives; \(d\) = distance from mean of negatives to cut-off; \(d\) = distance from mean of positives to cut-off; \(S_n\) = standard deviation of negatives; \(S_p\) = standard deviation of positives; \(\delta\) = delta, the distance of the mean of the sample population from the cut-off in standard deviation units. Delta for positive samples: \(\delta_p = d/S_p\); Delta for negative samples: \(\delta_n = d_n/S_n\).
negative population, $\delta_-=\delta_-/S_-;\text{ as the cut-off is defined as zero, this is equivalent to }\delta_-=X_-/S_-.$ Similarly, the delta for the positive population, $\delta_+=\delta_+/S_+;=X_+/$.

The advantages of expressing results in these terms, graphically and with the summary measure of $\delta_+$ and $\delta_-$ for the test, lie in the immediate ease of comparison of the ability of the test to distinguish positives from negatives and the correctness of the placement of its cut-off, and the fact that delta measures take into account each individual reading, and thus statistically summarise the results more accurately than do the traditional qualitative measures of sensitivity and specificity.

In addition, if a panel of specimens is tested with a particular kit, the mean and 95% confidence limits derived from the log distribution can be plotted on a linear scale as a Hi-Lo graph. This method is particularly useful for comparing the results obtained by a variety of tests on the same panel of sera and for quality control purposes. Fig. 4 shows the steps involved. With this style of presentation, three or more distributions can be depicted for comparison, and separation between positive and negative populations easily seen.

The delta value is particularly useful when attempting to distinguish between tests.
of high sensitivity and specificity. For example two ELISA tests, each correctly classifying all antibody positive and antibody negative samples of a coded panel of sera, would both be reported as showing 100% sensitivity and specificity. However, test A gave a delta of 4.60 for the antibody positive samples (i.e. $\delta$, 4.60) whereas test B produced a delta of 3.01 for the same samples (i.e. $\delta$, 3.01). According to statistical tables, the probability of test A is 99.99% for correctly identifying an antibody positive sample whereas test B has a probability of 99.87% for obtaining the correct result. There is less chance of test A producing a false negative result (0.01%) than test B (0.13%) when testing the same population.

The relationship of delta and the probability of a test producing the correct result can similarly be applied to the data for the antibody negative samples of the serum panel tested by both assays mentioned above. The test with the largest value for $\delta$, would be the test with the highest probability of obtaining the correct result when testing antibody negative subjects and the assay with the least chance of producing a false positive result.

Therefore, $\delta_{a}$ determines the probability of obtaining the correct result when testing antibody positive samples and can be viewed as a statistically derived estimate of sensitivity and $\delta_{b}$ determines the probability of obtaining the correct result when testing antibody negative samples and can be viewed as a statistically derived estimate of specificity.

The values of these principles in the evaluation of both first and second generation assays for anti-HIV is demonstrated in the following paper (Maskill et al., 1988).

Conclusion

Several principles of evaluation of diagnostic tests must be taken as axiomatic. These include consideration of sample size; consideration of what use the test will be put to, from which comes knowledge of what population it will be used in; and thus guidance in forming evaluation samples so as to be representative of this population.

With these requirements satisfied, it is important to consider the internal dynamics of the test, and thus the meaning of the results in relation to the biological characteristics they are derived from. Analysis and presentation of results of evaluations should then attempt to reflect these dynamics, and make clear the relationship between test and phenomena described. It is hoped that the method described in this paper will assist others in achieving these goals.

Acknowledgements

The authors wish to express their gratitude to the staff of the National Reference Laboratory for helpful criticisms of the text, to Mr. Ed Waldman and Mr. Witold Waldman for the preparation of the figures and to Barbara Gray for prep-
aration of the manuscript. The National AIDS Reference Laboratory is funded by a Special Grant from the Commonwealth Department of Community Services and Health.

References

An evaluation of competitive and second generation ELISA screening tests for antibody to HIV

William J. Maskill, Nick Crofts, Edward Waldman, David S. Healey, Teresa S. Howard, Colin Silvester and Ian D. Gust

National HIV Reference Laboratory (NRL), Fairfield Hospital, Fairfield, Victoria 3078, Australia
(Accepted 12 April 1988)

Summary

Two competitive anti-HIV ELISA screening assays (Behring and Wellcozyme) and two second generation assays using antigens generated by recombinant DNA technology (Abbott) and synthetic peptides (Biochrom) were evaluated against common panels of anti-HIV positive sera and sera known or thought likely to give false positive reactions. The assays were also tested on fresh sequential blood donations. Conventional estimates of sensitivity and specificity did not reveal a significant difference between the assays. Statistical analyses using log_{10} transformed data to determine delta values (the distance of the mean optical density (OD) ratio from the cut-off measured in standard deviation units) showed the Abbott assays to have the highest probability (>99.99%) of detecting anti-HIV positive samples and the Behring assay as having the highest probability (>99.99%) of correctly identifying anti-HIV negative specimens. The combined data from conventional estimates of sensitivity and specificity and delta values suggests that the Abbott assay is the test of choice for screening purposes.

Anti-HIV; ELISA; Evaluation; Delta

Introduction

Since the discovery of the human immunodeficiency virus (HIV), the causative agent of the acquired immunodeficiency syndrome (AIDS), many tests for the de-
tection of antibody to this virus (anti-HIV) have been developed and introduced into clinical practice (Weiss et al., 1985; Maskill et al., 1986).

The first generation screening tests were almost exclusively enzyme-linked immunosorbent assays (ELISA) in which disrupted virus particles were bound to a solid phase (usually the well of a microtitre plate) and the presence of antibodies in test sera detected by direct binding of labelled anti-human antibody.

Although these tests have achieved sensitivities and specificities in excess of 99%, because of the scale on which these tests are used in blood banks, false positive results, though rare, have major implications. These include permanent deferral of potential blood donors (even though the results of screening tests cannot be confirmed by supplementary assays), and the need to utilize a range of expensive supplemental tests to assist in the management of subjects who may or may not be infected (Kuhn et al., 1985; Crofts and Gust, 1987). Many first generation assays have also shown inadequate sensitivity especially for specimens taken at the early stages of infection (Saah et al., 1987).

A need therefore exists to develop assays which are more specific than the first generation of screening tests and are capable of detecting antibodies in the early stages of infection.

Two approaches have been followed in the development of improved assays. Firstly, indirect ELISAs have been replaced by competitive ELISAs in which patients' antibodies compete with labelled human anti-HIV for binding sites on HIV antigen fixed to a solid phase (Cheinsong-Popov et al., 1984). Secondly, purified viral lysates have been replaced by synthetic peptides (Gnann et al., 1987) or by antigens generated by recombinant DNA technology (Frosner et al., 1987).

We have evaluated four of the latest anti-HIV screening assays to become available in Australia, which represent each of these approaches. The assays are the Abbott recombinant HTLV-III EIA (Abbott Laboratories, North Chicago, IL), the Biochrom synthetic peptide anti-HIV EIA (Biochrom Berlin, F.R.G.), the Behring competitive anti-HIV EIA (Behringwerke AG, Marburg, F.R.G.) and the Wellcozyme monoclonal competitive anti-HIV EIA (Wellcome Diagnostics U.K.). These evaluations were carried out by a number of Australian Reference Laboratories and Blood Transfusion Services, in a study coordinated by the National HIV Reference Laboratory (NRL) at Fairfield Hospital, Melbourne.

We present here the results of the evaluations undertaken at the NRL and the Blood Transfusion Services.

Methods

The strategy of evaluation

Each assay was used to test a coded panel of 600 sera prepared by the NRL, and 1700-4500 fresh sequential donations in blood transfusion laboratories. Data from these studies was forwarded to the NRL and analysed using a DEC Microvax computer and in-house programs developed from Datatrieve (DEC, Sydney, Australia).
The panel

The panel of 600 sera selected by the NRL was made up of duplicate aliquots of 300 specimens presented under code. This panel comprised sera from 148 anti-HIV positive subjects which belonged to one of three clinical categories: Category A, patients with AIDS (50 sera); Category B, patients with clinical or laboratory evidence of disease, e.g. ARC (71 sera); Category C, infected individuals with no signs or symptoms of infection nor evidence of deficient cell mediated immunity (27 sera). Sera were also included from 52 subjects not infected with HIV but whose sera either had given or potentially could give false positive reactions on existing screening assays. Of the 52 sera, 40 had produced false positive EIA results with existing licensed assays and 12 sera were from patients or individuals in which EIA false positive reactions are common (patients infected with syphilis, legionella, brucella, Epstein Barr virus (EBV), herpes simplex virus (HSV), malaria, pregnant women, and pools of sera positive for rheumatoid factor, anti-streptolysin O (ASO), cold agglutinins, OX Weil-Felix, and a pool of sera which react with only the p55 band by Western blots (WB), all of which were obtained from healthy blood donors who had signed a declaration form stating that they were not members of any group considered to be at risk of infection with HIV). In addition, two sera not containing antibody to HIV and eight known to contain antibody were presented neat and in nine doubling dilutions titrated in a pool of normal human sera (NHS).

Subjects whose sera were included in the panel were designated as infected or uninfected on the basis of all available clinical, epidemiological and laboratory data including absolute and differential lymphocyte counts and both screening and supplementary assays for anti-HIV.

Serological analysis included an in-house WB assay using the LAV strain of HIV cultured in CEM cells (Commonwealth Serum Laboratories, Parkville, Australia) and three different radioimmunoprecipitation assays (RIP). Two of the RIP assays used purified 125I-labelled p24 viral antigen provided by Dr. L. Arthur (Frederick Cancer Research Facility, National Cancer Institute, MD. U.S.A.). The remaining RIP assay employed a recombinant 125I-labelled gp41 viral antigen (Centocor. Malvern, PA, U.S.A.).

One of the 125I p24 RIP assays and the 125I gp41 RIP assay were performed by staff of the Medical Virology Division, Institute of Medical and Veterinary Science, Adelaide.

Criteria for Western blot interpretation

Sera showing no reactivity or reactivity to non-viral bands were reported as negative. Sera showing reactivity to any of the glycoprotein antigens (gp41-45, gp 120, gp160) and to at least three other viral proteins (p12, p18, p24, p34, p40, p53, p55, p68) were reported as positive. Sera showing reactivity at viral specific bands which did not fulfill the criteria for a positive were reported as indeterminate.

Performance of the tests

The 600 coded specimens were tested at the NRL by four technicians, with different pairs performing each assay.
In each blood bank, the assays were performed in parallel with the assay that the blood bank was currently using. Any specimen reactive on either assay was forwarded to the NRL for further testing.

Each assay was performed according to the manufacturer's package insert. These are briefly described below:

The Abbott assay utilized a single bead coated with both recombinant DNA (rDNA) HIV core and envelope antigens derived from an *E. coli* expression vector. Coated beads were incubated with diluted (1:40) test sera for 30 min at 40°C, washed three times with 5 ml of distilled H₂O, and incubated with goat anti-human IgG, conjugated with horseradish peroxidase, for 30 min at 40°C. This was followed by further washing, addition of the substrate (o-phenylenediamine) and incubation at room temperature for 30 min. The reaction was stopped by the addition of 1 M H₂SO₄ and the optical density read at 492 nm.

The Biochrom assay is a conventional indirect ELISA: however, the antigen immobilized to the solid phase microtitre wells is a mixture of synthetic peptides which correspond to epitopes of HIV proteins p18, p24, gp41 and gp120. Diluted sera (1:40) were added to the wells of microtitre plates and incubated for 1 h at 37°C. The plates were washed four times with diluted wash buffer, incubated for 1 h at 37°C with sheep anti-human IgG conjugated with alkaline phosphatase. This was followed by further washing and the addition of the p-nitrophenyl-phosphate substrate and incubation at room temperature for 30 min. The reaction was stopped by addition of 3 M NaOH and the optical density read at 405 nm.

In the Behring competition assay, detergent-treated, heat-inactivated viral lysate prepared from a HIV infected H9 cell line was coated onto microtitre wells. Twenty-five microlitres of undiluted test serum and 100 µl of human anti-HIV conjugated to horseradish peroxidase were added to each well and incubated for 1 h at 37°C. Following 4 washes with diluted wash solution and addition of tetramethyldiaminobiphenyl dihydrochloride, the plates were incubated at room temperature for 30 min. The reaction was stopped by the addition of 3.5 M H₂SO₄ and the optical density read at 450 nm.

The Wellcozyme competition monoclonal assay differs from the Behring assay in that viral antigen is prepared from an HIV infected CEM cell line, disrupted by sonication, inactivated by treatment with β-propiolactone, and attached to the wells of microtitre plates with mouse monoclonal antibody. Test serum (50 µl) and human anti-HIV (75 µl) conjugated to horseradish peroxidase were added to each well and incubated for 1 h at 45°C. After washing four times with diluted wash fluid, 3,3',5,5'-tetramethylbenzidine and hydrogen peroxide were added to each well and the plates incubated for 20 min at room temperature. The reaction was stopped by the addition of 2 M H₂SO₄ and the optical density read at 450 nm.

Data analysis

Data were provided to the NRL in the form of optical density readings and cut-offs for each plate or run. Optical density (OD) ratios were calculated by dividing each reading by the relevant cut-off. For the Behring and Wellcozyme assays the reciprocal value was calculated.
The delta (δ) values for the anti-HIV positive and negative sample populations were calculated by dividing the mean OD ratio (log10) by the standard deviation of each population. This value provides a means of comparing how well the assays separate positive and negative populations from the cut-off. The higher the positive delta value obtained with anti-HIV positive sera, the higher the probability that the test will correctly identify such specimens; similarly, the higher the negative delta value obtained with a panel of anti-HIV negative sera, the higher the probability that the test will correctly identify antibody negative specimens. This measure has similarities to the indices described by Lusted (d') (1971) and Armitage (Δ) (1971) but overcomes the problem of dealing with populations having different variances. For further details concerning this method of analysis please refer to the previous paper in this issue (Crofts et al., 1988).

The mean end point titre for each kit determined from the titration series is defined as the highest dilution at which the mean OD ratio for all 8 anti-HIV positive sera was found to be above the cut-off.

Results

The log10 OD ratio data obtained from the testing of the anti-HIV positive and negative samples presented in the coded panel and that of the blood donors is shown in Fig. 1.

Fig. 1. Distribution of log10 OD ratios for anti-HIV positive sera (Δ—Δ), known and potential false positive sera (○—○), and anti-HIV negative blood donor sera (○—○). A = Abbott; B = Biochrom; C = Behring; D = Wellozyme.
With the Abbott and Biochrom assays, an artificial tightening of the spread of positive results is observed because most ELISA readers do not read above an OD of 2.0. In the Abbott assay, as all positive readings were at this upper limit, the variation in results was produced by the minor changes in the cut-off observed from run to run. For the Biochrom assay, the majority of positive results gave an OD of 2.0 or greater, producing a similar effect.

**Sensitivity**

The sensitivity of the four assays was evaluated on a panel of 148 sera obtained from subjects at various stages of infection with HIV. The results obtained are shown in Table 1.

The assay using synthetic peptides (Biochrom) found 144 of 148 known positive sera repeatably reactive, found 1 specimen to be not repeatably reactive and 3 sera repeatably negative. Each of the repeatably negative sera were from a patient with Category A AIDS in the terminal stage of the disease. When examined by WB, these sera were found to have antibodies to only gp41-45 and p55. The results obtained with the assay which employs antigen generated by recombinant DNA technology (Abbott Laboratories) were identical to the results obtained in the Reference Laboratory.

The two assays based on competitive inhibition detected the majority of infected individuals and produced discordant results (between duplicate aliquots examined under code) in only 5 or 6 of the 148 pairs of sera. Only one serum sample (from a patient with Category B infection) was found to be repeatably negative by one of the competitive assays (Behring). This sample, when tested by WB, contained antibodies reactive to all major HIV antigens.

The mean and 95% confidence limits of the OD ratios for sera from each of the clinical categories of disease are shown in Fig. 2. The largest variation of OD ra-

---

**TABLE 1**

Results of testing duplicate aliquots of 148 antibody positive and 52 antibody negative sera

<table>
<thead>
<tr>
<th>Clinical category</th>
<th>No. of sera</th>
<th>Results of duplicate tests</th>
<th>Abbott</th>
<th>Biochrom</th>
<th>Behring</th>
<th>Wellcozyme</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td>++</td>
<td>++</td>
<td>++</td>
<td>++</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Infected</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>A</td>
<td>50</td>
<td></td>
<td>50</td>
<td>47</td>
<td>46</td>
<td>46</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>0</td>
<td>3</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>0</td>
<td>0</td>
<td>50</td>
<td>0</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>B</td>
<td>71</td>
<td></td>
<td>71</td>
<td>70</td>
<td>68</td>
<td>67</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>0</td>
<td>1</td>
<td>1</td>
<td>4</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>0</td>
<td>0</td>
<td>16</td>
<td>0</td>
</tr>
<tr>
<td>C</td>
<td>27</td>
<td></td>
<td>27</td>
<td>27</td>
<td>27</td>
<td>26</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>0</td>
<td>0</td>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td>Total</td>
<td>148</td>
<td></td>
<td>148</td>
<td>144</td>
<td>141</td>
<td>143</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>0</td>
<td>3</td>
<td>6</td>
<td>5</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
</tbody>
</table>
| Uninfected (problem sera) | 52 | 0 | 51 | 1 | 51 | 0 | 5 | 47 | 0 | 0 | 52
Fig. 2. Means and 95% confidence limits of the OD ratios for each assay for sera obtained from patients at different stages of disease and for the known and potential false positive reactors. A = AIDS patients; B = Symptomatic anti-HIV positive patients; C = Asymptomatic anti-HIV positive patients; D = Known and potential false positive reactors.

tions was seen with the Biochrom and Behring assays, both of which also showed a decline in the mean OD ratio with progression of disease.

The sensitivity and 95% confidence limits for the sensitivity of each assay are given in Table 2.

The assays were also evaluated for their ability to detect anti-HIV in serially diluted sera. Fig. 3 shows the mean and 95% confidence limits of OD ratio values

<table>
<thead>
<tr>
<th>Kit</th>
<th>Sensitivity* (%)</th>
<th>95% C.L. Lower (%)</th>
<th>95% C.L. Upper (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Abbott</td>
<td>100.0</td>
<td>98.69</td>
<td>100.00</td>
</tr>
<tr>
<td>Biochrom</td>
<td>97.64</td>
<td>95.17</td>
<td>98.86</td>
</tr>
<tr>
<td>Behring</td>
<td>97.30</td>
<td>94.73</td>
<td>98.63</td>
</tr>
<tr>
<td>Welcozyme</td>
<td>98.31</td>
<td>96.08</td>
<td>99.28</td>
</tr>
</tbody>
</table>

* Calculated as the percentage of anti-HIV positive aliquots found reactive from the total number of aliquots tested (296).
obtained by each assay for each dilution of the 8 sera presented in titration.

Three assays (Abbott, Behring and Wellcozyme) gave mean titres of greater than 1:512 for all 8 sera whereas the remaining assay (Biochrom) gave a mean titre of 1:128.

Specificity

The specificity of the 4 assays was evaluated in two ways – by testing a small panel of 52 'problem sera' thought likely to produce false positive results, and by testing several thousand freshly collected units of blood.

One assay (Biochrom) found one of the 'problem sera' repeatably reactive. This specimen was obtained from an individual at low risk of infection and was reactive by a currently licensed screening assay. The sample showed an indeterminate band profile by WB. The remaining assays did not misclassify any of these sera, although the Behring assay detected non-repeatable reactivity in one of 5 separate serum pairs and the Abbott assay detected reactivity in one aliquot of a serum pair (see Table 1).

The mean and 95% confidence limits of the OD ratios for the 'problem sera' panel for each kit are shown in Fig. 2D.

Fig. 3. Mean and 95% confidence limits of OD ratio values for each assay at each dilution for the eight anti-HIV positive sera presented in titration. A = Abbott; B = Biochrom; C = Behring; D = Wellcozyme.
Initial and repeatable reactor rates from testing blood donations and specificity estimates

<table>
<thead>
<tr>
<th>Test</th>
<th>Donations tested</th>
<th>Specificity** 95% C.L.</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>Initially reactive</td>
<td>95% C.L.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Repeatably reactive*</td>
<td>Lower</td>
</tr>
<tr>
<td>Abbott</td>
<td>4455</td>
<td>8 (0.18)</td>
<td>1 (0.02)</td>
</tr>
<tr>
<td>Biochrom</td>
<td>2981</td>
<td>41 (1.38)</td>
<td>5 (0.17)</td>
</tr>
<tr>
<td>Behring</td>
<td>3531</td>
<td>7 (0.20)</td>
<td>1 (0.03)</td>
</tr>
<tr>
<td>Wellcozyme</td>
<td>1770</td>
<td>6 (0.34)</td>
<td>4 (0.23)</td>
</tr>
</tbody>
</table>

* None of the repeatably reactive sera tested by Western blot were found positive.
** Calculated from the number of donor sera tested minus those found repeatably reactive.

Table 3 illustrates the prevalence of initially reactive and repeatably reactive specimens detected when large panels of freshly collected plasma specimens from volunteer blood donors were tested. The frequency of repeatably reactive sera detected by the two competition assays ranged from 0.23% (Wellcozyme) to 0.03% (Behring) while the figures obtained with the assays based on rDNA (Abbott) and synthetic peptide technology (Biochrom) were 0.02% and 0.17%, respectively.

None of the blood donor specimens which were found to be repeatably reactive were positive by WB using the criteria currently recommended by the National Reference Laboratory. The specificity and 95% confidence limits for the specificity of each assay are also shown in Table 3.

Delta values

Recently we reported on a new method of comparing the performance of anti-HIV assays which involves analysis of log-transformed data (see previous paper in this issue). Briefly the performance of an assay is evaluated on a large panel of sera from subjects who are known to be infected or known to be free of infection. The ability of the test to distinguish the two populations is defined by units known as delta. Delta is the distance of the mean OD ratio of a sample population from the cut-off measured in standard deviation units.

The delta values obtained for each test for the anti-HIV positive sera from each of the clinical category of disease, for anti-HIV positive sera of all categories combined (total), for the known and potential false positive reactors and for the blood donations are given in Table 4.

Discussion

In the present study we report on four of the most recent assays to become available in Australia which represent two different approaches to improving anti-HIV ELISA screening assays. These are competition ELISAs (Behring and Wellcozyme) and second generation tests, which utilize antigens generated by recombinant DNA technology (Abbott) and synthetic peptides (Biochrom).
TABLE 4
Delta values produced by each kit for anti-HIV positive and negative serum sample populations

<table>
<thead>
<tr>
<th>Kit</th>
<th>Antibody positive sera</th>
<th>Antibody negative sera</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>A</td>
<td>B</td>
</tr>
<tr>
<td>Abbott</td>
<td>72.75</td>
<td>72.92</td>
</tr>
<tr>
<td>Biochrom</td>
<td>2.17</td>
<td>6.30</td>
</tr>
<tr>
<td>Behring</td>
<td>2.17</td>
<td>2.18</td>
</tr>
<tr>
<td>Welcozyme</td>
<td>4.23</td>
<td>3.31</td>
</tr>
</tbody>
</table>

* Clinical category of patients from whom sera was obtained.

A comparison of the log_{10} OD ratio distributions for known anti-HIV positive and negative sera and problem sera (see Fig. 1) demonstrates the ability of the four assays to discriminate between the three populations. The Abbott test produced clearest separation of anti-HIV positive and negative sera with no overlap between the two populations. The three other tests (Biochrom, Behring and Welcozyme) displayed some degree of overlap due to both repeatable and non-repeatable false negative and/or false positive results. In general, non-repeatable results (i.e. one aliquot found to be positive, the other negative) are due to technical errors, whereas false positive or false negative results which occur on both occasions are due to biological causes. On this basis, very few biological false negative results were obtained by the three kits (see Table 1). Western blot analysis of the repeatable false negative sera suggests that the Biochrom assay may encounter difficulty with sera which show reactivity predominantly to HIV glycoprotein antigens such as those obtained from AIDS patients at the terminal stages of disease.

The performance of the four assays on the panel of anti-HIV positive sera suggests that the Abbott assay has the highest sensitivity and Behring the lowest (see Table 2). However, after considering the 95% confidence limits for these sensitivities, it is not possible in a sample of this size to distinguish or rank the kits from highest to lowest sensitivity.

The four assays showed some variation in OD ratio values for the sera obtained from patients at different stages of disease. With the exception of the Abbott and Welcozyme assays, which were equally reliable in each clinical category, the performance of the other two tests (Biochrom and Behring) tended to diminish with progression of disease (see Fig. 2A, B and C).

The data from the titration of eight anti-HIV positive sera did not give end point titres for the Abbott, Behring and Welcozyme assays but showed a mean titre of 1:128 for the Biochrom assay. The most consistent and reproducible results (as evidenced by the least variation in OD ratios at each dilution) were obtained with the Abbott and Welcozyme assays (see Fig. 3). It should be noted that although the sera presented in titration represent a variety of different reactivities with different WB profiles, the results are not generalizable because it is not known how representative such sera are. Also, end point titre estimated on a few sera does not necessarily mirror the ability of an assay to detect antibody in patients early in the disease (Chenebaux and Delagneau, 1986).
Each assay performed well on the 'problem sera' which either had given or were thought likely to give false positive reactions with ELISA screening tests. The Wellcozyme assay found all 52 'problem sera' repeatedly negative. The Abbott, Behring and Biochrom assays found 1 to 5 sera reactive on at least one occasion while the Biochrom assay found 1 of these sera repeatably reactive (see Table 1). The clearest separation of the 'problem sera' from the anti-HIV positive samples was obtained by the Abbott assay (see Fig. 1). The least variation of OD ratios was observed with the Abbott and Wellcozyme assay. The Wellcozyme assay produced the closest mean OD ratio to the cut-off of all four kits for the 'problem sera' but the highly reproducible performance of the assay resulted in a tight clustering of OD ratios thus producing minimal variation (see Fig. 2D).

The performance of the four assays on the large panels of freshly collected plasma specimens from volunteer blood donors suggests that the Abbott and Behring assays have the highest specificity. However, when considering the 95% confidence limits for these specificities it is not possible to distinguish or rank the kits from highest to lowest specificity.

When comparing quantitative assays such as ELISAs it is often more useful to deal with the actual values (OD ratios) rather than the qualitative relationship to the cut-off, i.e. positive or negative. This enables a statistical approach to the estimation of sensitivity and specificity.

Accordingly we have developed such an approach by determining sensitivity and specificity in terms of delta (6), the distance of the mean OD ratio of antibody positive and antibody negative sample populations from the cut-off measured in standard deviation units (Crofts et al., 1988).

The delta values shown in Table 4 reflect the observations previously made concerning sensitivity, specificity, and reproducibility of the assays but have the advantage of providing a quantitative measurement for these parameters.

The Abbott assay shows the highest and most consistent positive delta values for sera obtained from patients at different stages of disease. The high delta value shown by this assay for all combined patient categories reflects the consistently high OD ratios which resulted in the clear separation of this population from the cut-off as shown in Fig. 1. The high positive delta values shown by the Abbott assay increases the confidence that can be placed in the sensitivity estimates shown in Table 2. Although assay to assay differences in these estimates are not statistically significant, the extremely large positive delta values for the Abbott assay show that there is a much greater tolerance in this test for variation of test results without the occurrence of false negatives. This provides the Abbott assay with a larger margin for variation than the other three assays when testing anti-HIV positive sera and ensures a consistent high level of sensitivity.

The decline in mean OD ratios and wide variation (low reproducibility) in OD ratios shown by the Behring and Biochrom assays with progression of disease status (see Fig. 2A, B and C) are clearly reflected in the delta values for these assays.

The Behring assay produced the largest variation in OD ratios for sera from all disease stages and this is shown by the consistently low delta values for this assay. The Wellcozyme assay performed equally well on sera from all disease stages showing low variation in OD ratios.
Comparison of delta values on the 'problem sera' shows that the Wellcozyme assay clearly separated this population from the cut-off. The delta values also show that the Behring test gave the clearest separation of the anti-HIV negative blood donor sera from the cut-off as shown by the high negative delta value for this population (see Table 4). The delta value provides a quantitative measure of the separation shown in Fig. 1C. Calculations using the delta values show this assay to have a probability of greater than 99.99% for correctly identifying anti-HIV negative samples. This increases the confidence that can be placed in the specificity estimates shown in Table 3. Although the specificity estimates for the four assays are not significantly different, the large negative delta value for the Behring assay indicates that it has a greater margin for variation than the other assays without the occurrence of false positives which ensures a reproducibly high level of specificity. This advantage, however, was somewhat diminished when testing problem sera (Table 4).

Demands for improvements in sensitivity and specificity of anti-HIV screening assays have recently been made (Saah et al., 1987; Meyer and Pauker, 1987). The conventional means of determining sensitivity and specificity of assays under evaluation does not use all the available data but relies upon qualitative estimates, namely, 'how many did the test get right or wrong?'. The use of delta values described in this study provides a quantitative measure which can be used in conjunction with the conventional estimates of kit performance to determine if improvements in sensitivity and specificity have been achieved.

Of the second generation assays the Abbott assay produced the clearest separation of anti-HIV positive and negative sera and showed the highest levels of sensitivity, specificity and smallest variation of OD ratios. Large positive delta values reflect the ability of the assay to consistently produce high OD ratios for anti-HIV positive sera taken from patients at different stages of disease. Calculations using these delta values show this assay to have a probability of greater than 99.99% of detecting anti-HIV positive individuals. This is an improvement by comparison with previously reported performance levels (Gurtler et al., 1987).

The relatively low delta value obtained by the Abbott test for both the blood donor and 'problem sera' leaves only a small margin for OD ratio variation. Calculations derived from the delta values show that the false positive rate could be as high as 0.21% if adequate laboratory technique is not maintained. In this evaluation the observed false positive rate in the blood donor population was 0.02%. This is a marked improvement in comparison to previously reported performance levels (Gurtler et al., 1987).

Of the two competition assays the Wellcozyme assay showed the highest levels of sensitivity which was also reflected in the relatively higher positive delta values. By contrast, the Behring assay showed the highest level of specificity of the two assays and this was confirmed by the large negative delta values reported for the blood donor samples. The Behring assay may encounter difficulty with 'problem sera' as shown by the number of non-repeatably reactive aliquots and the very low negative delta value for these sera (see Tables 1 and 4).

In conclusion, conventional estimates of sensitivity and specificity and the use
of delta values derived from this evaluation suggest that the Abbott recombinant assay provides marked improvements in the sensitivity of previously available assays and that competitive anti-HIV ELISA methods offer the greatest potential for improvements in specificity. Although the Abbott recombinant assay showed a high level of specificity in this evaluation, careful attention to technical aspects of the procedure will be necessary in order to maintain such levels of performance.

Acknowledgements

The authors wish to express their gratitude to Miss H. Huynh and Mrs. M. Karakaltsas of the NRL for performing the Western blots, to Mr. D. Worswick and Mr. L. Mckan for performing the RIP assays carried out at the Institute of Medical and Veterinary Science, Adelaide, to staff of the laboratories of the Australian Red Cross Blood Transfusion Services in Brisbane, Sydney, Melbourne, Adelaide and Perth, to Mr. Chris Birch for helpful comments in preparing this paper, to Mr. W. Waldman for preparation of the figures and to Barbara Gray for typing of the manuscript.

The National HIV Reference Laboratory is funded by a Special Grant from the Commonwealth Department of Community Services and Health.

References

CONFERECE ATTENDEES

Julie Ackerman  
Research Scientist  
Bio-Rad Laboratories  
1000 Alfred Nobel Drive  
Hercules, CA 94547  
(415) 724-5665

Jeanne Baldwin  
Product Manager  
Abbott Laboratories  
23272 Mill Creek Road, St. 200  
Laguna Hills, CA 92653  
(714) 472-2457

Steve Alexander, Ph.D.  
Director of Product Technology  
Cambridge Biotech  
1600 E. Gude Drive  
Rockville, MD 20850  
(301) 251-0800

Connie Ballard  
Lab Manager  
Home Office Reference Laboratory  
8915 Quivira Road  
Overland Park, KS 66215  
(913) 681-8856

Marion Alleman  
Lab. Mgr. Virology  
Louisiana Department of Health  
325 Loyola Avenue 7th Floor  
New Orleans, Louisiana 70112  
(504) 568-5374

Greg Ballish  
Product Manager  
Ortho Diagnostic Systems Inc.  
Retroviral Products, Route 202 North  
Raritan, NJ 08502  
(908) 704-3628

Diane Anderson  
Organon Teknika  
100 Akzo Avenue  
Durham, NC 27704  
(919) 620-2394

J. Dean Barry  
Lab Manager  
Virus Reference Laboratory, Inc.  
7540 Louis Pasteur  
San Antonio, TX 78229  
(512) 696-5510

David Anderson, M.D., Ph.D.  
Walter Reed Hospital  
Washington, D.C.

Vonni Barton  
Idaho State Health Laboratory  
2220 Old Penitentiary Road  
Boise, ID 83712  
(208) 334-2235

Tom Armstrong  
595 Anglum Dr., Dept. 031  
Hazelwood, MO 63042

Lisa Bauman  
Genetic Systems  
6565 185th Ave., NE  
Redmond, WA 98052  
(206) 861-5054

Michael S. Ascher, M.D.  
Deputy Chief  
Viral & Rickettsial Disease Laboratory  
2151 Berkeley Way  
Berkeley, CA 94704  
(415) 540-2580

Sara T. Beatrice, Ph.D.  
Director  
NY City Department of Health  
Room 374, 455 First Avenue  
New York, NY 10016  
(212) 340-4581

Walt Back  
Lab Director  
Division of Laboratories, CO Dept. of Health  
4210 E. 11th Avenue  
Denver, CO 80220  
(303) 331-4740

Arthor Aseltine  
Microbiologist  
Vermont Department of Health  
195 Colchester Avenue, Box 70  
Burlington, VT 05402  
(802) 863-7337

James L. Beebe  
Chief Microbiologist  
Division of Laboratories, CO Dept. of Health  
4210 E. 11th Avenue  
Denver, CO 80220  
(303) 331-4740
CONFERENCE ATTENDEES

Julie Ackerman  
Research Scientist  
Bio-Rad Laboratories  
1000 Alfred Nobel Drive  
Hercules, CA  94547  
(415) 724-5665

Jeanne Baldwin  
Product Manager  
Abbott Laboratories  
23272 Mill Creek Road, St. 200  
Laguna Hills, CA  92653  
(714) 472-2457

Steve Alexander, Ph.D.  
Director of Product Technology  
Cambridge Biotech  
1600 E. Gude Drive  
Rockville, MD  20850  
(301) 251-0800

Connie Ballard  
Lab Manager  
Home Office Reference Laboratory  
8915 Quivira Road  
Overland Park, KS  66215  
(913) 681-8856

Marion Alleman  
Lab. Mgr. Virology  
Louisiana Department of Health  
325 Loyola Avenue 7th Floor  
New Orleans, Louisiana  70112  
(504) 568-5374

Greg Ballish  
Product Manager  
Ortho Diagnostic Systems Inc.  
Retroviral Products, Route 202 North  
Raritan, NJ  08850  
(908) 704-3628

Diane Anderson  
Organon Teknika  
100 Akzo Avenue  
Durham, NC  27704  
(919) 620-2394

J. Dean Barry  
Lab Manager  
Virus Reference Laboratory, Inc.  
7540 Louis Pasteur  
San Antonio, TX  78229  
(512) 696-5510

David Anderson, M.D., Ph.D.  
Walter Reed Hospital  
Washington, D.C.

Vonntita Barton  
Idaho State Health Laboratory  
2220 Old Penitentiary Road  
Boise, ID  83712  
(208) 334-2235

Tom Armstrong  
595 Anglum Dr., Dept. 031  
Hazelwood, MO  63042

Lisa Bauman  
Genetic Systems  
6565 185th Ave., NE  
Redmond, WA  98052  
(206) 861-5054

Michael S. Ascher, M.D.  
Deputy Chief  
Viral & Rickettsial Disease Laboratory  
2151 Berkeley Way  
Berkeley, CA  94704  
(415) 540-2580

Sara T. Beatrice, Ph.D.  
Director  
NY City Department of Health  
Room 374, 455 First Avenue  
New York, NY  10016  
(212) 340-4581

Dwight Aseltine  
Microbiologist  
Vermont Department of Health  
195 Colchester Avenue, Box 70  
Burlington, VT  05402  
(802) 863-7337

James L. Beebe  
Chief Microbiologist  
Division of Laboratories, CO Dept. of Health  
4210 E. 11th Avenue  
Denver, CO  80220  
(303) 331-4740

Arthur Back  
Lab Director  
San Francisco Department of Public Health  
101 Grove Street, #419  
San Francisco, CA  94102  
(415) 554-2800

Hazelwood, MO  63042

Berkeley, CA  94704  
(415) 540-2580

Redmond, WA  98052  
(206) 861-5054

Burlington, VT  05402  
(802) 863-7337

San Francisco, CA  94102  
(415) 554-2800
Cindy Collins
Director, Marketing
Baxter Diagnostics Inc.
909 Orchard Street
Mundelein, IL  60060
(708) 949-6700

Carlyn L. Collins, M.D., M.P.H.
Chief, Lab Training Branch
Centers for Disease Control
1600 Clifton Road, Mailstop A16
Atlanta, GA  30333
(404) 639-3230

Anne Marie Comeau, Ph.D.
Co-PI Newborn HIV
TSRI, Massachusetts
305 South Street
Jamaica Plain, MA  02130
(617) 522-3700 x152

Mark C. Connelly, Ph.D.
Sr. Scientist
Ortho Diagnostic Systems
Orthomune Research, Route 202
Raritan, NJ  08869
(908) 704-3651

James M. Conroy
Research Scientist
NYS Department of Health
Empire State Plaza, P.O. Box 509
Albany, NY  12201
(518) 474-8579

Jerome Cordts
Executive Director
ASTPHLD
1211 Connecticut Avenue, NW, Suite 508
Washington, D.C.  20036
(202) 822-5227

Cynthia Cossen
Public Health Microbiologist
Viral & Rickettsial Dis. Lab., CA Dept. Hlth.
2151 Berkeley Way
Berkeley, CA  94704
(415) 540-2348

G. David Cross
Health Scientist
Centers for Disease Control
1600 Clifton Road, NE, MS G23
Atlanta, GA  30333
(404) 639-2824

Sandra Currin
Microbiology Laboratory Supervisor
Dept. of Gen. Svcs., Consolidated Lab Svcs.
1 North 14th Street
Richmond, VA  23219
786-5143

Steve Dahl
Abbott Diagnostics
1 Abbott Park Road
Abbott Park, IL  60064

Clem Darrow
Organon Teknika
100 Akzo Avenue
Durham, NC  27704
(919) 620-2308

Gioacchino DeChirico
Ortho Diagnostic Systems, Inc.
Route 202
Raritan, NJ  08869

Denise Deines
Organon Teknika
100 Akzo Avenue
Durham, NC  27704

Steve Delaney, Ph.D.
Abbott Laboratories
1 Abbott Park Road, Dept. 9YH, Building AP-8B
Abbott Park, IL  60064-3500
(708) 937-0941

Susanne D. DesRosiers
HIV Laboratory Supervisor
New Hampshire Public Health Laboratory
Health & Welfare Bldg., 6 Hazen Drive
Concord, NH  03301
(603) 271-4620

Arthur DiSalvo, M.D.
Laboratory Director
Nevada State Health Laboratory
1660 N Virginia Street
Reno, NV  89503
(702) 688-1335

P. David Dotson, Jr.
Chief, Virology-Immunology
Indiana State Board of Health
1330 W. Michigan Street
Indianapolis, IN  46206
(317) 633-0246

Harold Dowda
Dir., Diag. Micro.
SC Department of Health
8231 Parklane Road
Columbia, SC  29223
(803) 935-7002
Kenneth P. Dressier, Ph.D.
Director, Technical Services
New York Blood Center
310 E. 67th Street
New York, NY 10021
570-3080

Chyang Fang, Ph.D.
Director, NRLID
American Red Cross
15601 Crabbs Branch Way
Rockville, MD 20855
(301) 738-0534

Arlette Faquex
Scientist
WHO, Global Programme on AIDS
CH-1211
Geneva, 27
Switzerland
41-22-791-3858

Carol Ferrera
Genetic Systems
6565 185th Avenue, NE
Redmond, WA 98052
(206) 881-8300

Dennis V. Ferrero, M.P.H.
Director, Public Health Laboratory
San Joaquin County, California
P.O. Box 2009/1601 E. Hazelton Avenue
Stockton, CA 95201
(209) 468-3460

Bill Fleming
Marketing Director
Epitope, Inc.
8505 SW Creekside Place
Beaverton, OR 97005-7108
(503) 641-6115

Bagher Forghani, Ph.D.
Res. Scientist
Viral and Rickettsial Disease Laboratory
CA Dept. of Hlth. Svcs., 2151 Berkeley Way
Berkeley, CA 94704
(415) 540-2561

Fritz Friedhoff
Genetic Systems
6565 185th Avenue, NE
Redmond, WA 98052

Dana Gallo
P.H. Microbiologist
California Department Health Services
2151 Berkeley Way
Berkeley, CA 94704
(415) 540-2818

Margarita Garcia
Medical Technologist
Department of Health of Puerto Rico
Call Box STD, Caparra Heights Station
San Juan, PR 00922
(809) 754-8124

Myriam Garcia
Laboratory Director
Department of Health of Puerto Rico
Call Box STD, Caparra Heights Station
San Juan, PR 00922
(809) 754-8124

Patricia E. Garrett, Ph.D.
Director, Reg. Affairs & Special Projects
Boston Biomedica, Inc.
375 West Street
West Bridgewater, MA 02379
(508) 580-1900

J. Ronald Genevieve
Chief Microbiologist
Ohio Department of Health Laboratory
P.O. Box 2568
Columbus, Ohio 43216-2568
(614) 421-1078 X55

J. Richard George, Ph.D.
Chief, Developmental Technology Section
The Centers for Disease Control
Bldg 1, Rm 2385, MS D12, 1600 Clifton Rd., NE
Atlanta, GA 30333
(404) 639-3647

A. Russell Gerber, M.D.
1663 Knob Hill Ct., NE
Atlanta, GA 30329
(404) 325-6911

Jane Getchell
Assistant Director
Iowa Hygienic Laboratory
The University of Iowa
Iowa City, Iowa 52242
(319) 335-4500

James A. Gibson, M.P.H.
250 Carver Ln.
Lebanon, TN 37087
449-2319

Marjorie Giles
Public Health Microbiologist
Los Angeles County Public Health Laboratory
313 North Figueroa Street, Room 1234
Los Angeles, CA 90012
Robert K. Gleeson, M.D.
Medical Director
Northwestern Mutual Life Insurance
720 E. Wisconsin Avenue, Rm E9R
Milwaukee, WI 53202
(414) 271-1444

W. Harry Hannon, Ph.D.
Chief, Clinical Biochemistry
Centers for Disease Control
1600 Clifton Road, Mailstop F19
Atlanta, GA 30316
(404) 488-4132

George F. Grady, M.D.
PI-Newborn HIV Proj.
TSRI/MA State Lab
305 South Street
Jamaica Plain, MA 02130
(617) 522-3700

Margaret Hanson
Memorial Blood Center of Minneapolis
2304 Park Avenue
Minneapolis, MN 55404
(612) 871-3300

Tim Granade
Centers for Disease Control
1600 Clifton Rd., Bldg. 1, Room 2250, MS D12
Atlanta, GA 30333

Sherry Harris
Ortho Diagnostic Systems, Inc.
Route 202
Raritan, NJ 08869

Dr. Pat Hays
Sr. Public Health Sci.
Kansas Health & Environmental Laboratories
Forbes Building 740
Topeka, KS 66620
(913) 296-1644

Samuel B. Gregorio, Dr.P.H., SM(AAM)
Microbiology Branch Manager
Division Lab. Svcs., Dept. of Health Services
275 E. Main Street
Frankfort, KY 40621
(502) 564-4446

Richard L. Heberling, Ph.D.
Virus Reference Laboratory, Inc.
7540 Louis Pasteur
San Antonio, TX 78229
(512) 696-5510

Brigitte Griffith, Ph.D.
Chief Retrovirus Section
Virology Reference Lab., VA Medical Center
950 Campbell Avenue
West Haven, CT 06516
(203) 932-5711 x744

Theresa L. Hodges
Sr. Public Health Laboratory Scientist
KS Department of Health and Environment
Building 740, Forbes Field
Topeka, KS 66620
(913) 296-1640

Kamlesh Gupta
Federal Center for AIDS
301 Elkin Street
Ottawa, Ontario K1A OL2
Canada

Gerald L. Hoff, Ph.D.
Epidemiologist
Kansas City Health Department
1423 E. Linwood Boulevard
Kansas City, MO 64109
(414) 923-2600

Nancy J. Haley, Ph.D.
Assoc. Dir.
Metropolitan Life Insurance Company
Elmsford Testing Lab, 4 Westchester Plaza
Elmsford, NY 10523
(914) 347-3251

Xinyue Hou, M.D.
Disease Control Service, Denver Dept. of P.H.
605 Bannock Street
Denver, CO 80204
(303) 893-7051

Doug House
Cambridge Biotech
1600 E Gude Dr.
Rockville, MD 20850
Howard I. Kim  
Technical Director  
Damon Laboratories  
1011 Rancho Cucamonga Boulevard  
Newbury Park, CA 91320  
(805) 498-3181  

Warren L. Kleinsasser, M.D.  
Senior Vice President and Medical Director  
Osborn Laboratories  
14901 West 117th Street  
Olathe, KS 66062  
(913) 764-5555  

Charles Konigsberg, M.D., M.P.H.  
Director, Division of Health  
KS Dept. of Health and the Environment  
Forbes Building, #740  
Topeka, KS 66620  

Monica Krieger  
Genetic Systems  
6565 185th Avenue, NE  
Redmond, WA  98073-9716  
(206) 881-8300  

Jerry Kudlac  
Director, Microbiology  
Oklahoma State Department of Health  
P.O. Box 24106  
Oklahoma City, OK 73124  
(405) 271-5070  

Mary Kuhns, M.D.  
Chief Scientist  
Abbott Laboratories  
1 Abbott Park Road  
Abbott Park, Illinois 60064-3500  

Martial LaCroix  
IAF Bio Chem  
531, boul. des Prairies  
Laval, Quebec H7N 423  
(514) 687-4910  

John Lankford  
Abbott Laboratories  
Abbott Park  
Abbott Park, IL 60064-3500  
(708) 937-0171  

Keith Lawrence  
Administrator  
New York City Department of Health  
455 First Avenue  
New York, NY 10016  
(212) 340-4581  

Dale Lawrence, M.D.  
Chief, Clinical Development Section  
National Institute of Allergy & Infect. Dis.  
Rockville, MD  

Francis Lee, Ph.D.  
Assistant Professor  
Pediatric Infectious Diseases, Emory Univer.  
69 Butler Street, SE  
Atlanta, GA 30303  
(404) 589-4997  

Taun-Kong Lee, Dr.P.H.  
Micro Supervisor  
Public Health Laboratory Dept. Human Services  
221 State Street, Station 12  
Augusta, ME 04333  
289-2727  

Dr. Helen H. Lee  
825 Morningside  
Lake Forest, IL 60045  

Sadie Lehr  
Microbiologist  
Oregon Public Health Laboratory  
1717 SW 10th Avenue  
Portland, OR 97201  
(503) 229-5882  

Debbie Lepine  
Biologist  
Federal Centre For AIDS  
Virus Building, Tunney's Pasture  
Ottawa, Ontario K1A OL2  
Canada  
(613) 957-0173  

Andrew Levin, Ph.D.  
President  
Immunetics  
380 Green Street  
Cambridge, MA 02139  
(617) 492-5416  

Robert Lindner, Ph.D., M.D.  
Medical Director  
Division of Laboratories, IL Dept. of P.H.  
Chicago, IL  
(312) 793-4760  

Bill Link  
Group Leader  
Bio-Rad Laboratories  
1000 Alfred Nobel Drive  
Hercules, CA 94547  
(415) 724-7000
Shyh-Ching Lo, Ph.D., M.D.
Chief, Division of Geographic Pathology
Armed Forces Institute of Pathology
Washington, D.C.

Carl W. Ludvigsen, Jr., M.D., Ph.D., J.D., FCAP, FGLM
Senior Vice President and Chief Pathologist
Home Office Reference Laboratory
P.O. Box 2035
Shawnee Mission, KS 66201
(913) 888-1770

James P. Lugo, Ph.D.
Product Manager
Bio-Rad Laboratories
3726 Miraloma Avenue
Anaheim, CA 92806
(714) 630-6400

H. Craig Lyerla, Ph.D.
Microbiologist
Centers for Disease Control
1600 Clifton Road, Mailstop A16
Atlanta, GA 30333
(404) 639-3898

Ron Lynch
Director, Marketing
Ortho Diagnostic Systems, Inc.
Route 202
Raritan, NJ 08869
(201) 218-8702

Dr. Jim Mahony
Virologist
St. Joseph’s Hospital
50 Charlton Avenue East
Hamilton, Ontario L8N 4A6
Canada
(416) 522-4941 x3166

Eugene Malone
Illinois Dept. of P.H.
2121 W. Taylor St.
Chicago, IL 60612
(312) 793-1052

David Marshman
Marketing Associate
Genetic Systems
6565 185th Avenue, NE
Redmond, WA 98052
(206) 861-5064

Robert Martin, Dr.P.H.
Lab. Director
Michigan Department of Public Health
3500 N. Logan Street, P.O. Box 30035
Lansing, MI 48909
(517) 335-8067

Sandy Marubio
Area Resource Director
National Laboratory Training Network
2121 West Taylor Street
Chicago, IL 60612
(312) 793-3306

Jeffrey Massey
Microbiologist
Michigan Department of Public Health
3500 N. Logan Street, P.O. Box 30035
Lansing, MI 48909
(517) 335-8135

Donald Mayo
Chief Virologist
Connecticut State Department of Health
10 Clinton Street
Hartford, CT 06144
(203) 566-4776

Patsy McCarty, MT (ASCP)
Division Director
Mississippi Public Health Laboratory
P.O. Box 1700, 2423 North State Street
Jackson, MS 39216
(601) 960-7582

Bruce J. McCreedy, Ph.D.
Associate Director
Roche Biomedical Labs, Inc.
1912 Alexander Drive, P.O. Box 13973
Research Triangle Park, NC 27709
(919) 361-7796

Lisa T. McFarland
Project Coordinator
Program Resources, Inc.
P.O. Box 12794
Research Triangle Park, NC 27709
(919) 549-8330

J. Todd McPherson
Director
Disease Control Lab. Division
IN State Board of Hlth., 1330 W. Michigan St.
Indianapolis, IN 46202
(317) 633-0252

Dr. Kathleen L. Meckstroth
Lab Director
Department of Health
500 E. Capitol
Pierre, SD 57501
(605) 773-3368

Peyton S. Metzel, Ph.D.
Independent Consultant
1962 Pinehurst Ct.
Libertyville, IL 60048
(708) 680-9363
Dr. Frank J. Michalaki, Ph.D.
Metpath Virology Lab
1 Malcolm Avenue
Teterboro, NJ 07608
(201) 393-5870

Douglas A. Michels
Director, Marketing AIDS/Hepatitis
Ortho Diagnostic Systems, Inc.
Route 202
Raritan, NJ 08869
(201) 218-8506

William S. Miller
Consultant
5618 St. Albans Way
Baltimore, MD 21212
(301) 435-9417

Gregory Milman
Chief
Pathogenesis Branch
Division of AIDS-Natl Institute of Hlth NIAID
Bethesda, MD 20892
(301) 496-8378

Barry Mitchell
Chief, HIV Serology
Texas Department of Health
1100 West 49th Street
Austin, TX 78756
(512) 458-7657

Craig Modde
Syva
900 Arastradero Road, Mailstop 1-215
Palo Alto, CA 94303
(314) 638-8703

Rick Moody
Director, Serology
Alabama Public Health Department
8140 University Drive
Montgomery, Alabama 36130
(205) 277-8660

Dr. Philip P. Mortimer
PHLS Virus Reference Laboratory
61 Colindale Avenue
London NW9 SHT
UK
081-300-4400

Susan Mottice
Director, Microbiology
Utah State Division of Laboratory Services
44 Medical Drive
Salt Lake City, Utah 84113
(801) 584-8300

Dr. Patricia Necessary
Sr. Research Scientist
Home Office Reference Laboratory
10310 W. 84th Terr
Lenexa, KS 66214
(913) 888-1770

Lawrence Nelson
Nevada Public Health Laboratory
1660 N Virginia Street
Reno, NV 89503

Sherian Nestor
Microbiologist II
WV Bureau of P.H., Office of Laboratory Svcs.
167 11th Avenue
South Charleston, WV 25303
(304) 348-3530

Peter Neumann
Head Retrovirus Lab
Federal Centre for AIDS
Virus Laboratory, Tunney's Pasture
Ottawa, Ontario K1A OL2
Canada
(613) 957-0173

Richard H. Newhouse
Vice President, Lab Services
Serologicals, Inc.
780 Park North Boulevard, Suite 120
Clarkston, GA 30021
(404) 296-5595

Evelyn Nichol
Baxter Health Care
909 Orchard St.
Mundelein, IL 60060

Janet K A Nicholson, Ph.D.
Center for Infectious Diseases
Centers for Disease Control
Atlanta, Georgia 30333

Nazih Nuwayhid
Assistant Director
Veterans Administration Medical Center
Texas Tech. University HSC-Internal Medicine
Amarillo, TX 79106
(806) 354-5487

S. O'Connor
Ortho Diagnostic Systems Inc.
Route 202
Raritan, NJ 08869

Debbie Oronzio
Pharmacia Diagnostics Inc.
350 Passaic Avenue
Fairfield, NJ 07004
Ken Ostrander  
Damon Clinical Laboratories  
115 Fourth Avenue  
Needham Heights, MA 02194

Gary W. Oty  
Principal Scientist IB  
New Mexico Scientific Laboratory Division  
700 Camino de Salud, NE, P.O. Box 4700  
Albuquerque, NM 87196-4700  
(505) 841-2535

Terri Ozegovich  
Genetic Systems  
6565 185th Avenue, NE  
Redmond, WA 98052

Percy S. Pan  
Marketing Services Manager  
Cambridge Biotech  
1600 E. Gude Drive  
Rockville, MD 20850  
(301) 251-0800

Elizabeth Parker  
Virology Supervisor  
DHEC-Bureau of Labs  
8231 Parklane Road  
Columbia, SC 29223  
(803) 935-7054

James L. Pearson, Dr.P.H.  
Director, Consolidated Laboratories  
ND Dept. of Hlth. & Consolidated Laboratories  
2635 East Main  
Bismarck, ND 58505  
(701) 221-6140

K. Michael Peddecord, Dr.P.H.  
Director  
Laboratory Assurance Program  
Graduate School of P.H., San Diego State U.  
San Diego, CA 92182  
(619) 594-5006

John R. Pfister  
Retrovirus Supervisor  
State Laboratory of Hygiene  
465 Henry Mall  
Madison, WI 53706  
(608) 262-2358

Theodore E. Plucinski, M.D.  
Vice President - Chief MD  
The Equitable  
Two Penn Plaza  
New York, NY 10121  
(212) 714-5346

Wolf Prensky, Ph.D.  
28-10 High St.  
Fair Lawn, NJ 07410

Max R. Proffitt, Ph.D.  
Director, Section of Clinical Virology  
Dept. of Microbio., Cleveland Clinic Fdn.  
One Clinic Center, 9500 Euclid Avenue  
Cleveland, Ohio 44195-5140  
(216) 444-8237

Jane Rachel  
St. Lukes Hospital  
28 W 69th Street  
Kansas City, MO 64113

Steven Raia  
Vice President, Marketing & Sales  
Boston Biomedica, Inc.  
375 West Street  
West Bridgewater, MA 02379  
(508) 580-1900

Michael Ramirez  
Microbiologist  
Hygienic Laboratory  
University of Iowa  
Iowa City, Iowa 52242  
(319) 335-4500

Martha A. Redus  
4530 Bob's Court  
Stone Mountain, GA 30083

Barry S. Reed, M.D.  
Medical Director  
Metropolitan Life Insurance Company  
One Madison Avenue  
New York, NY 10010  
(212) 578-2373

Dave Reilly  
Bio-Rad Laboratories  
1000 Alfred Nobel Drive  
Hercules, CA 94547

Marion Reuter  
Division of Laboratories, CO Dept. of Health  
4210 E. 11th Avenue  
Denver, CO 80220

Karen L. Richards  
Clinical Research Associate  
Syva  
900 Arastadero  
Palo Alto, CA 94304  
(415) 354-2374
Caterina Sellitto
Immuncits
380 Green Street
Cambridge, MA  02139
(617) 492-5416

Richard Steece, Ph.D.
Assistant Director
P.H. Laboratory Division - Health Department
717 SE Delaware Street
Minneapolis, MN  55440
(612) 623-5640

Jill Senne-Giesick
Co. of San Diego
1600 Pacific Highway
San Diego, CA  92101

Miriam Steller
Cambridge Biotech
1600 E Gude Dr.
Rockville, MD  20850

Judy Sheldon
Director, Specialty Products
Serologicals, Inc.
780 Park North Boulevard, Suite 120
Clakston, GA  30021
(404) 296-5595

Roy Stevens, Ph.D.
Research Scientist
Wadsworth Laboratories
Box 509, Empire State Plaza
Albany, NY  12201
(518) 474-7281

Haynes W. Sheppard, Ph.D.
Research Scientist
Viral & Rickettsial Disease Lab/CDHS
2151 Berkeley Way
Berkeley, CA  94704
(415) 540-2821

Pat Stewart
Genetic Systems
6565 185th Avenue, NE
Redmond, WA  98052
(206) 881-8300

R. Ken Shockley, Ph.D.
Dir., R & D
Murex Corporation
3075 Northwoods Circle
Norcross, GA  30071
(404) 662-0660

Dr. Robert L. Stout
Clinical Reference Laboratory
11850 W 85th St.
Lenexa, KS  66214

Mark Sieczkarek
General Manager
Genetic Systems
6565 185th Avenue, NE
Redmond, WA  98052
(206) 881-5100

Susan Stramer, Ph.D.
Section Manager
Abbott Laboratories
Rt. 137 and 43
Abbott Park, IL  60064
(708) 937-6272

William Slanta
Serology Manager
Arizona State Laboratory
1520 W. Adams
Phoenix, AZ  85007
(602) 542-6123

Henry L. Strother
Chief, Serology/Virology
State Public Health Laboratory
307 W. McCarty Street
Jefferson City, MO  65101
(314) 751-0633

Mel Smith
State Department of Health
P.O. Box 2755
Lincoln, NE  68502

Steven Stump
Bio-Rad Laboratories
1000 Alfred Nobel Drive
Hercules, CA  94547

Catherine L. Spruill
874 Burns Circle
Lilburn, GA  30247

Roger N. Taylor
Centers for Disease Control
1600 Clifton Road
Atlanta, GA  30333

Larry Staples
Product Manager
Abbott Diagnostica
4535 Lake Forest Drive, Suite 640
Cincinnati, Ohio  45241
(513) 563-0771

Gary E. Tegtmeyer, Ph.D.
Director of Research
Community Blood Center of Greater Kansas City
4040 Main Street
Kansas City, MO  64111
(816) 753-4040
Gary Toedter, Ph.D.
Coulter Immunology
440 W. 20th Street
Hialeah, FL 33010
(305) 883-6880

Ann Toledo
Division Manager
Program Resources Inc
P.O. Box 12194
Research Triangle Park, NC 27709
(919) 549-8330

Anne J. Ulm
Administrative Manager
ASTPHLD
1211 Connecticut Avenue, NW, Suite 508
Washington, D.C. 20036
(202) 822-5227

Guido van der Groen
Dept. of Micro., Institute of Tropical Med.
Nationalestraat 155-2000
Antwerpen
Belgium
32.3.247.66.66

Wallis M. Velleca
Microbiologist
Centers for Disease Control
1600 Clifton Road, N.E.
Atlanta, GA 30333
(404) 639-2823

John Vernasco
Product Manager
Abbott Diagnostics
111 Barclay Blvd., Suite 100
Lincolnshire, IL 60069
(800) 323-9100

Dolores B. Villarreal
Microbiologist
Washington State Department of Health
1610 N.E. 150th Street
Seattle, WA 98155
(206) 361-2876

Richard Walkenbach
PHLS
Missouri State Public Health Laboratory
307 West McCarty Street
Jefferson City, MO 65101
(314) 751-0633

Dr. Michael Wandall
Director of Business Development
Genetic Systems
6565 185th Avenue, NE
Redmond, WA 98052

John G. Warhol
223 First Ave.
Atlantic Highlands, NJ 07716

Joe Washart
Coulter Electronics Inc.
P.O. Box 2145
Hialeah, FL 33012
(305) 888-0131 x2619

Jeff Webb
Kansas Health Department
1900 East 9th
Kansas 67214

Barbara J. Weiblen, M.S.
Senior Scientist
TSRI/MA State Laboratory
305 South Street
Boston, MA 02130
(617) 522-3700

Steve Weiss
Abbott Diagnostics
1 Abbott Park Road
Abbott Park, IL 60064
(708) 937-0232

Stephanie Wells
Market Manager
Syva Company
900 Arastradero Road, Mailstop 1-215
Palo Alto, CA 94304
(415) 354-2141

Barbara G. Werner, Ph.D.
Massachusetts State Laboratory Institute
305 South Street
Boston, MA 02130
(617) 522-3700 x212

Jane Westerman
Assoc. Dir. Mktg.
Organon Teknika Corporation
100 Akzo Avenue
Durham, NC 27704
(919) 620-2326

Judith A. Wethers, M.S.
Dir. of Testing Services
Retrovirology Laboratory, NY State D.O.H.
WCL&R, Empire State Plaza, P.O. Box 509
Albany, NY 12201
(518) 474-2163
Judith Wilber, Ph.D.
Manager, Clinical Microbiology
Chiron Corporation
4560 Horton Street
Emeryville, CA 94608
(415) 655-8730 x4468

Dr. John A. Wilhelm
Institute Virion
Weingartenstr 9, CH-8803 Ruschlikon
Ruschlikon 08803
Switzerland
41-1-724-0965

J. Stephen Williams
Lab Manager
Georgia Department of Human Resources
47 Trinity Avenue, S.W.
Atlanta, GA 30334
(404) 656-4781

Dave Wyllie
Damon Clinical Laboratories
115 4th Avenue
Needham Heights, MA 02194

Jo Ann L. Yee
Serology Supervisor
University of California, Davis
Dept. of Medical Pathology, U of California
Davis, CA 95616
(916) 752-8242

Madonna Young
Senior Technologist
Nichol's Institute
32961 Calle Perfecto
San Juan Capistrana, CA 92679
(714) 661-8000

Susanne Zanto, MT (ASCP)
Virology/Serology Supervisor
Montana Public Health Laboratory
Cogswell Building
Helena, Montana 59620
(406) 444-2642
Introduction

The constant evolution of testing methodologies for the human retroviruses demands that periodic reviews of the capabilities of these methodologies used in the public health laboratories be conducted. To this end, the Association of State and Territorial Public Health Laboratory Directors (ASTPHLD) sponsored the Sixth Conference on Human Retrovirus Testing March 5-7, 1991, in Kansas City, Missouri. Approximately 285 conference participants viewed 36 poster presentations, heard 12 plenary session speakers discuss a variety of topics relevant to retrovirus testing, and participated in six panel sessions concentrating on the most relevant topics of human retrovirus testing.

Panel Session 1 was entitled "Testing for HIV-1." Topics discussed included rapid testing methods, western blots, testing of nontraditional samples, surrogate markers, recombinant/synthetic-based assays, western blot interpretation criteria, indirect fluorescent antibody methods, and viral detection methods.

Panel Session 2 was entitled "Polymerase Chain Reaction." Topics discussed within this panel session included methodologies used in PCR, quality assurance, proficiency testing, and test interpretation and reporting.

Panel Session 3 concentrated on developments within its title, "Flow Cytometry." The topics covered included flow cytometry for disease staging, monitoring antiviral therapy, training, quality assurance, reporting criteria, and interpretation.

Panel Session 4 was entitled "Testing for HIV-2 and HTLV-I/HTLV-II." Topics covered included HTLV-I and HTLV-II differentiation, the confirmation methodologies and criteria for HIV-1 and HIV-2 as opposed to the HTLV viruses, HIV-1 and HIV-2 combination tests, and alternate rapid testing methods.

Panel Session 5 was entitled "The Diagnosis of HIV Infection in Newborns." The topics covered, in a very specific sense, were the use of flow cytometry, PCR, and culture assays to enhance the detection of infection in newborns. Discussions also covered the use of ELISPOT, in vitro assays, and analysis for IgA.

Panel Session 6 was entitled "Standards of Practice and Reporting." A new topic covered during this session was the interpretation and reporting of EIA reactives in vaccinated individuals.

There continues to be intense interest in the methodologies discussed in these six panel sessions. In addition, the increased attention by the medical and scientific community is focused on early intervention and treatment programs for HIV-positive patients. Title III of the Ryan White CARE Act outlines provisions for monitoring the immune status of HIV-positive patients in order to assess the stage of the acquired immunodeficiency syndrome (AIDS). Laboratory analysis, in all aspects of this monitoring process, are extremely important. Laboratory findings form the basis of the therapies currently available for retrovirus-infected individuals.

It is intended that the recommendations derived from the Conference on Testing for Human Retrovirus be used universally to set laboratory standards in methodologies, policies, quality assurance, interpretation, and reporting.
SUMMARY OF SURVEY #8

To assess the current status of testing for human retroviruses, a survey was sent to 54 state and territorial public health laboratories during the third quarter of 1990. The survey requested data for fiscal year 1990 (July 1989-June 1990). In previous years, calendar-year data were requested.

A milestone was achieved in gathering the data for this most recent survey. All 54 state and territorial public health laboratories and the City of New York contributed to the survey data. This had not occurred in any previous year. The summary of these data follows.

The total number of enzyme immunoassay (EIA) tests as indicated in Table 1 totalled in excess of 4 million. These data cannot be compared directly with the data from previous years because these tests include data from 99 California clinical laboratories and blood banks. However, in evaluating these data, it can be noted that the EIA reactive rate in the national sample is 3%. Western blot confirmation of the reactives was 58%; 9% of the western blots were indeterminate. Using indirect fluorescent antibody (IFA), 79% of the reactives were confirmed; 1.5% were indeterminate.

Removing the California data generates Table 2, demonstrating 3.175 million EIA tests. These data indicate a slightly higher reaction rate of 3.5%. Western blot confirmation also is higher; positive in 82%; and indeterminate in 7.5%. By IFA, 78% of the original EIA reactive tests were confirmed, while only 1.5% were indeterminate. These data appear to demonstrate superior sensitivity and specificity of the IFA testing methodologies.

Figure 1 indicates the total number of tests done by each of the responding laboratories. The data indicate that approximately 48% of the laboratories conduct less than 50,000 tests per year. Sixteen percent conduct greater than 100,000 tests per year; approximately 35% of the responding laboratories conduct 50,000 to 100,000 tests for retrovirus per year.

The human immunodeficiency virus (HIV) positivity rate reported by public health laboratories is shown in Figure 2. Of the responding laboratories, 42% have a very low positivity rate of less than 1%. Another 42% of the responding laboratories indicate a positivity rate between 1% and 5%; 17% of laboratories have a positivity rate in excess of 5%. The pie chart depicted in Figure 3 indicates the tests that are used to confirm EIA reactives. These data show that the western blot test was used most frequently (73% of all confirmatory tests conducted). The IFA confirmatory system was used for 26% of the reactive tests, while approximately 1% of the confirmations were conducted with either polymerase chain reaction (PCR) or culture techniques.

Figure 4 indicates that alternate testing methodologies are being used by more laboratories. Surrogate markers, which include p24 antigen, neopterin, and β2-microglobulin, are used by eight laboratories. Flow cytometry, culture, polymerase chain reaction (PCR), recombinant antigen, and synthetic peptides also are being used, but in fewer numbers of laboratories.

Public health laboratories continue to support the initiative of the Centers for Disease Control (CDC) in gathering data for the family seroprevalence surveys. Figure 5 indicates that 35 laboratories conducted HIV testing in populations of women of childbearing age.

**TABLE 1**

<table>
<thead>
<tr>
<th>Test</th>
<th>Total</th>
<th>Reactive</th>
<th>IND†</th>
</tr>
</thead>
<tbody>
<tr>
<td>EIA†</td>
<td>4,424,943</td>
<td>132,376</td>
<td>N/A</td>
</tr>
<tr>
<td>WB**</td>
<td>131,890</td>
<td>77,075</td>
<td>11,625</td>
</tr>
<tr>
<td>IFA††</td>
<td>35,221</td>
<td>27,831</td>
<td>559</td>
</tr>
</tbody>
</table>

* Includes 37 county (local) public health laboratories and 99 clinical laboratories in California.
† Indeterminant.
†† Enzyme immunoassay.
** Western blot.
††† Indirect fluorescent antibody.

**TABLE 2**

<table>
<thead>
<tr>
<th>Test</th>
<th>Total</th>
<th>Reactive</th>
<th>IND*</th>
</tr>
</thead>
<tbody>
<tr>
<td>EIA†</td>
<td>3,175,534</td>
<td>111,479</td>
<td>N/A</td>
</tr>
<tr>
<td>WB†</td>
<td>91,375</td>
<td>26,664</td>
<td>555</td>
</tr>
<tr>
<td>IFA**</td>
<td>33,934</td>
<td>22,640</td>
<td>555</td>
</tr>
</tbody>
</table>

* Indeterminant.
† Enzyme immunoassay.
†† Western blot.
** Indirect fluorescent antibody.

**FIGURE 1.** Total number of tests performed by reporting laboratories.

**FIGURE 2.** HIV positivity rates for tests in public health laboratories.

The data indicate that the positivity rate in this population is substantially below that seen in the adult population shown in Figure 2. Of 35 labs reporting, only one laboratory indicated that the positive rate in this population was greater than 1%.

Figure 6 outlines the retrovirus testing being conducted in each of the responding laboratories. A total of 52 responding laboratories indicated that they conduct tests for HIV-1 (Pennsylvania and Minnesota state public health laboratories do not conduct HIV testing). The data in this figure indicate that there are six laboratories conducting HIV-2 testing and 11 laboratories performing tests for HTLV-I/II.

Table 3 shows the total number of HIV2 tests conducted. Of the 4,460 EIA tests, only 114, or 2.5%, were found to be reactive. This reactive rate is similar...
FIGURE 5. The HIV positivity rate for newborns.

FIGURE 6. Summary of the public health laboratory retrovirus testing. Note, in two states, the HIV-1 is not performed in the state laboratory.

FIGURE 7. Testing turnaround time for nonreactive results.

FIGURE 8. Testing turnaround time for reactive results.

TABLE 3
HIV-2 Retrovirus Testing*

<table>
<thead>
<tr>
<th>Test</th>
<th>Total</th>
<th>Reactive</th>
<th>IND†</th>
</tr>
</thead>
<tbody>
<tr>
<td>EIA‡</td>
<td>4,460</td>
<td>114</td>
<td>N/A</td>
</tr>
<tr>
<td>WB**</td>
<td>194</td>
<td>22</td>
<td>32</td>
</tr>
<tr>
<td>IFA††</td>
<td>17</td>
<td>0</td>
<td>1</td>
</tr>
</tbody>
</table>

* Includes local laboratories in California.
† Indeterminant.
‡ Enzyme immunoassay.
** Western blot.
†† Indirect fluorescent antibody.

Less than 1% were reactive. Those reactive specimens, which were then confirmed by western blot, showed a 25% confirmatory rate, while 11% were indeterminate. In using the IFA methodology, 55% were confirmed, while 6% were indeterminate.

Figure 7 demonstrates the average testing turnaround time when the results of the EIA tests are negative. Most laboratories indicate that the results are reported within three calendar days. The testing turnaround time for an EIA positive specimen is longer and more inconsistent (Figure 8). It is clearly evident that extended periods of time are needed to confirm results; the largest number of laboratories (11) indicated that seven calendar days were needed in order to report a confirmed positive result. This extended turnaround time is a source of frequent discussion between the state public health laboratory and the acquired immunodeficiency syndrome (AIDS) program in each of the states and territories. Many requests have been made to consider various schemes to reduce the reporting turnaround time when positive EIA results are involved.

The principal manufacturers of EIA testing rea-
TABLE 4
HTLV-I/II RETROVIRUS TESTING *

<table>
<thead>
<tr>
<th>Test</th>
<th>Total</th>
<th>Reactive</th>
<th>IND†</th>
</tr>
</thead>
<tbody>
<tr>
<td>EIA‡</td>
<td>523,524**</td>
<td>1,946</td>
<td>N/A</td>
</tr>
<tr>
<td>WB††</td>
<td>1,702</td>
<td>407</td>
<td>195</td>
</tr>
<tr>
<td>IFA‡‡</td>
<td>1,942</td>
<td>1,063</td>
<td>112</td>
</tr>
</tbody>
</table>

* Includes the 37 local public health and 99 clinical laboratories in California.
† Indeterminate.
‡ Enzyme immunoassay.
** Of this total, 515,093 were performed by 35 clinical laboratories in California.
‡‡ Western blot.

TABLE 5
SUPPLIERS OF EIA* USED BY STATE PUBLIC HEALTH LABORATORIES

<table>
<thead>
<tr>
<th>Abbott</th>
</tr>
</thead>
<tbody>
<tr>
<td>DuPont</td>
</tr>
<tr>
<td>Genetic Systems</td>
</tr>
<tr>
<td>Organon Teknika</td>
</tr>
<tr>
<td>Ortho</td>
</tr>
</tbody>
</table>

* Enzyme immunoassay.

TABLE 6
SUPPLIERS OF WB* REAGENTS USED BY STATE PUBLIC HEALTH LABORATORIES

<table>
<thead>
<tr>
<th>Abbott</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bio-Rad</td>
</tr>
<tr>
<td>Cappell</td>
</tr>
<tr>
<td>DuPont</td>
</tr>
<tr>
<td>Epitope (Organon Teknika)</td>
</tr>
<tr>
<td>Genetic Systems</td>
</tr>
<tr>
<td>Ortho</td>
</tr>
</tbody>
</table>

* Western blot.

TABLE 7
US ARMY HIV-1 TESTING FOR FISCAL YEAR 1990

<table>
<thead>
<tr>
<th>Test</th>
<th>Total</th>
<th>Reactive</th>
<th>IND*</th>
</tr>
</thead>
<tbody>
<tr>
<td>EIA†</td>
<td>1,304,224</td>
<td>6,012</td>
<td>N/A</td>
</tr>
<tr>
<td>WB‡</td>
<td>6,875</td>
<td>2,278</td>
<td>863</td>
</tr>
<tr>
<td>Culture</td>
<td>2,417</td>
<td>1,092</td>
<td></td>
</tr>
<tr>
<td>PCR**</td>
<td>657</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Flow††</td>
<td>7,500</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

* Indeterminate.
† Enzyme immunoassay.
‡ Western blot.
** Polymerase chain reaction.
†† Flow cytometry.

TABLE 8
US ARMY HIV-2 TESTING FOR FISCAL YEAR 1990

<table>
<thead>
<tr>
<th>Test</th>
<th>Total</th>
<th>Reactive</th>
<th>IND*</th>
</tr>
</thead>
<tbody>
<tr>
<td>EIA†</td>
<td>1,590</td>
<td>16</td>
<td>N/A</td>
</tr>
<tr>
<td>WB‡</td>
<td>16</td>
<td>0</td>
<td>1</td>
</tr>
<tr>
<td>PCR**</td>
<td>5</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Flow††</td>
<td>10</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

* Indeterminate.
† Enzyme immunoassay.
‡ Western blot.
** Polymerase chain reaction.
†† Flow cytometry.

TABLE 9
US ARMY CONFIRMATORY HTLV-I/II TESTS FOR FISCAL YEAR 1990

<table>
<thead>
<tr>
<th>Test</th>
<th>Total</th>
<th>Positive</th>
</tr>
</thead>
<tbody>
<tr>
<td>Culture</td>
<td>15</td>
<td>8</td>
</tr>
<tr>
<td>PCR*</td>
<td>177</td>
<td></td>
</tr>
<tr>
<td>Flow†</td>
<td>100</td>
<td></td>
</tr>
</tbody>
</table>

* Polymerase chain reaction.
† Flow cytometry.

gent for public health laboratories are listed in alphabetical order in Table 5. The leading suppliers of western blot testing systems are indicated in Table 6.

Survey data also contained the following information. Six state laboratories are performing flow cytometry, while 11 plan to initiate the procedure within the next 12 months. Of the six laboratories currently performing flow cytometry, two test all HIV-positive samples. Thirty-nine laboratories (75%) participate in the CDC family of surveys. Ninety-two percent of the responding laboratories follow the recommendation of ASTPHLD-CDC in performing and interpreting the western blot. Twenty-eight percent of the responding laboratories routinely request a second sample in order to confirm a positive test result. Only one state (Michigan) has laws regarding HIV testing of pregnant women.

Tables 7, 8, and 9 represent, respectively, the HIV-2, HIV-2, and HTLV-I/II testing done by the US Army. Although not a member of ASTPHLD, the US Army testing laboratories represent a considerable amount of testing performed on members of the armed forces. These data are significant in that this is an excellent cross-section of the young adult population of the United States. The Army data are included for comparison.
TESTING (HIV-1)

CHAIR
J. Mehsen Joseph, PhD, Director, Laboratories Administration, Maryland Department of Health and Mental Hygiene, Baltimore, Maryland.

MEMBERS
Cynthia K. Cossen, Public Health Microbiologist, Viral and Rickettsial Diseases Laboratory, Department of Health, Berkeley, California; J. Richard George, PhD, Chief, Developmental Technology Section, Centers for Disease Control, Atlanta, Georgia; Stephen Josephson, PhD, Director, Clinical Microbiology/Virology, Rhode Island Hospital, Providence, Rhode Island (Rapporteur).

TOPICS
Rapid testing methods; blots; testing of nontraditional samples; surrogate markers; recombinant/synthetic-based assays; simultaneous detection methods; western blot criteria; IFA; viral detection methods.

RECOMMENDATIONS
1.01 Rapid tests for the detection of HIV-1 antibody not be a waived test under CLIA regulations. It is essential that a proficiency testing program be developed to ensure the quality of testing.
1.02 At the present time, we cannot recommend the use of urine or saliva specimens for HIV antibody testing. Available data, however, indicate that these specimens may be acceptable. We recommend that manufacturers and interested investigators publish in peer-reviewed journals and submit data to the FDA that would allow urine and saliva to be used for HIV antibody testing.
1.03 We encourage manufacturers to evaluate nontraditional markers, such as p17 antigen, and develop quantitative assays for staging.
1.04 FDA-licensed recombinant or synthetic peptide ELISA tests for the detection of HIV-1 antibody can be used in an HIV-1 algorithm. The following algorithm has been proposed as an alternative to the existing algorithm for the detection of HIV-1 antibody. This algorithm should be evaluated during the coming year and data submitted at the next meeting.
a. HIV-1 ELISA A
   1. Negative—Report
   2. Reactive—Go to b
b. HIV-1 ELISA B
   1. Negative—Report
   2. Reactive—Go to c or d
c. HIV-1 IFA
   1. Positive—Report
   2. Negative or nonspecific—To WB and/or follow-up specimen
d. HIV-1 WB
   1. Positive—Report
   2. Indeterminate—Go to follow-up specimen
   3. Negative—Report or repeat
1.05 The ASTPHLD criteria for western blot interpretation should be re-evaluated in light of recent reports of uninfected individuals with envelope only or envelope and gag bands. The issue of contamination by another specimen may be a contributing factor and must be addressed.
1.06 Quantitative antigen assays for measuring virus burden are needed to monitor disease progression and efficacy of therapy. Further development of better quantitative assays should be encouraged. It is recommended that a national
reference standard for antigen quantitation be
developed for use by manufacturers for standard-
izing their antigen detection kits.
1.07 IFA has a place in HIV diagnostic schemes as a
supplemental test. Some of the currently availa-
ble commercial kits show promise for use as
confirmatory tests.
1.08 Laboratories with significant experience with
HIV IFA may use their own IFA-based protocols
for confirmation of screening test results.
1.09 Nonspecific IFA results should be clarified when-
ever possible. The use of absorption will resolve
many of these problems, and manufacturers are
couraged to develop standard protocols for
this and to make cells available for this purpose.
Other supplemental tests should be used when
absorption cannot resolve the antibody status of
a specimen. A positive IFA can be reported as
positive. However, a negative or a nonspecific
result should be followed by an additional sup-
plemental test.
1.10 The IFA should not be used as a screening
procedure.
1.11 IFA kit manufacturers are encouraged to submit
their products to the FDA for licensure. Public
health and other laboratories are encouraged to
actively participate in gathering data needed to
support these applications.
1.12 The following references should be used for
delta value calculations:
immunosorbent assays: a method of data
tive and second-generation ELISA. J Virol
POLYMERASE CHAIN REACTION

CHAIR

Haynes W. (Chip) Sheppard, PhD, Research Scientist, California Public Health Foundation, Berkeley, California.

MEMBERS

Anne M. Comeau, PhD, Co-Principal Investigator, Newborn HIV Project, Theobald Smith Research Institute, Jamaica Plain, Massachusetts (Rapporteur); Harold Dowda, PhD, Director, Diagnostic Microbiology, South Carolina Department of Health and Environmental Control, Columbia, South Carolina; Robert Martin, DrPH, Director of Laboratories, Michigan Department of Health, Lansing, Michigan; Susan Mottice, PhD, Director, Microbiology, Utah State Health Department, Salt Lake City, Utah; John Pfister, RM (AAM), Retrovirus Supervisor, State Laboratory of Hygiene, Madison, Wisconsin.

TOPICS

Quality assurance; methodology; applications; interpretation/reporting; proficiency testing.

RECOMMENDATIONS

2.01 For specimens obtained "on site," with same-day processing, EDTA, Heparin, or ACD are suitable. For specimens that are shipped from another site, samples in ACD may be suitable for up to five days. For specimens in EDTA or heparin, the maximum transport time is 48 hours.

2.02 Every effort should be made to obtain whole blood samples 24 hours to 48 hours after venipuncture. Samples should be transported at room temperature.

2.03 Dried blood spots appear to be suitable for PCR testing and may be stable for long periods of time. Further data are awaited regarding the sensitivity and specificity of PCR testing from dried blood spots.

2.04 Magnesium concentration must be optimized for each set of primers. Current primers: 1.5 mM to 2.5 mM.

2.05 Annealing and extension conditions must be optimized in each laboratory.

2.06 The number of cycles in the amplification process should be between 30 and 35 for HIV detection.

2.07 Liquid oligonucleotide hybridization (OH) is a highly sensitive and specific detection method and is recommended.

2.08 A variety of nonradioactive detection methods are now available and some have sensitivity and specificity comparable to OH detection. Further comparative testing is recommended.

2.09 In order to obtain the authority to perform and report PCR results, the PCR subcommittee recommends initiation and continuation of discussions with those who hold patents affecting the use of PCR for the purpose of ensuring continuation of public health investigations of the diagnosis, etiology, and pathogenesis of diseases of public health importance.

2.10 Laboratories performing PCR should employ a minimum of two primer pairs for initial testing and/or resolution of discrepant results.

2.11 Primers with documented sensitivity and specificity should be used.

2.12 A minimum of two separate PCR reactions (two primer pairs or duplicates of one primer pair) should be performed for each specimen. Splitting of the original specimen is recommended when possible.

2.13 Discrepant results should be resolved by additional analysis of the original specimen using the same or different primer pairs. If discrepant results cannot be resolved by repeat testing, the results should be reported as indeterminate and another specimen should be requested.

2.14 The overall interpretation of PCR testing should be reported as HIV DNA detected, HIV DNA not detected, or indeterminate.

2.15 Complete testing algorithms need not be reported.

From the Sixth Conference on Human Retrovirus Testing, March 5-7, 1991, Kansas City, Missouri.
2.16 Appropriate positive, negative, and reagent controls should be included with every PCR test.
2.17 All published guidelines for minimizing the contamination of specimens with amplified PCR product should be rigorously followed.
2.18 Biochemical sterilization of PCR products should be instituted in all PCR laboratories as soon as possible.
2.19 The committee recommends that each laboratory performing PCR conduct validation studies on an appropriate number of well-characterized test samples and maintain appropriate records of such test results.
2.20 The development of validation panels for distribution to PCR laboratories by the private sector, NIH, and CDC is recommended.
2.21 The development of standardized reagents and controls in the form of commercial kits is encouraged.
2.22 The immediate initiation of a proficiency testing program for PCR is recommended.
2.23 The application of PCR, in combination with other tests, for the diagnosis of infants born to seropositive mothers is recommended. Additional studies on the use of PCR in the first three months of life are needed.
2.24 The use of PCR for retroviral diagnosis in "high risk" seronegative adults is not recommended as a routine procedure.
2.25 The use of PCR for the resolution of indeterminate serology in adults is not recommended as a routine procedure.
2.26 PCR may be helpful in the diagnosis of rare individuals with defective antibody production.
2.27 PCR is useful for the differentiation of viral subtypes (e.g., HTVL-I/II or HIV-1 versus HIV-2).
2.28 The determination of viral burden by PCR may be helpful in the prognosis of HIV disease. However, quantitative PCR requires complex procedures that are not established in most laboratories.
2.29 The use of PCR to monitor the effects of antiviral therapy on viral burden is an important area of future study but has not been validated at this time.
FLOW CYTOMETRY

CHAIR

Jonathan M. Kagan, PhD, Chief, Clinical Sciences Section, Treatment Research Program, Division of Acquired Immunodeficiency Syndrome (AIDS), National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland.

MEMBERS

A. Russell Gerber, MD, Center for Infectious Diseases, Centers for Disease Control, Atlanta, Georgia; Janet K.A. Nicholson, PhD, Center for Infectious Diseases, Centers for Disease Control, Atlanta, Georgia (Rapporteur).

TOPICS

Quality assurance; training; monitoring antiviral therapy; reporting criteria and interpretation; disease staging.

RECOMMENDATIONS

3.01 Each public health laboratory should evaluate the need to establish flow cytometry capability based on an assessment of criteria including: prevalence of HIV infection and cumulative incidence of AIDS within the area served; ability to monitor and evaluate the quality of flow cytometry and pertinent hematology results; cost effectiveness; and the availability of other early HIV intervention services. Additional data are needed before specific recommendations can be made on nonretroviral public health and environmental applications of flow cytometry.

3.02 Flow cytometry training should be mandatory for all relevant personnel including instrument operators, laboratory supervisors and laboratory directors.

a. All instrument operators should, in addition to flow cytometer manufacturer’s training, receive supplementary training through additional courses or workshops offered by independent organizations. In-house training at experienced laboratories may be an acceptable alternative.

b. Clinical flow cytometry training courses for laboratory directors and supervisors should be developed.

c. The ASTPHLD recommends the development of certification programs for laboratory technicians trained in flow cytometry.

d. The ASTPHLD recommends the development and implementation of accreditation standards for all training courses and workshops in clinical flow cytometry.

3.03 The ASTPHLD should assemble and make available updated information on clinical flow cytometry training courses and workshops.

3.04 Before accepting specimens for clinical flow cytometric analysis, each laboratory must have in place a comprehensive quality assurance protocol that includes standardization, quality control procedures, and proficiency testing.

a. Standardization of instrument optical alignment, spectral sensitivity, and fluorescence compensation must be performed daily.

b. Quality control includes daily monitoring and recording of instrument performance and cell preparation methodologies. Reagent stability should be assessed with lot changes and as otherwise needed.

c. Proficiency testing within a nationally recognized program on a quarterly basis is required as an integral component of comprehensive quality assurance.


3.06 The determination of absolute counts for lymphocyte subsets requires both hematologic and flow cytometric measures. For hematologic measures:

From the Sixth Conference on Human Retrovirus Testing, March 5-7, 1991, Kansas City, Missouri.
a. Determination of the absolute lymphocyte count requires both a white blood cell count (WBC) and a differential (including percent lymphocytes). The ASTPHLD endorses the NCCLS Tentative Standard (1984), H-20T, Leukocyte Differential Counting. The optimal specimen for these hematologic measures is EDTA-preserved whole blood (lavender top tube) less than six hours old.

b. Recognizing that laboratories may receive hematologic specimens more than six hours old, the ASTPHLD recommends consideration of the following options:

1. Hematologic analysis may be performed within six hours locally, and a second specimen (drawn simultaneously) for flow cytometry may be transported to the flow cytometry laboratory. It may be desirable to obtain a fresh smear for quality assurance.

2. Laboratories can verify the maximum age of specimens for which hematologic results are comparable to fresh specimens.

c. The laboratory performing the hematologic analysis should maintain a documented intralaboratory coefficient of variation of less than five percent for the WBC.

d. Laboratories should evaluate and characterize intralaboratory bias and establish confidence intervals for the WBC and the differential lymphocyte counts.

e. Automated differentials are strongly recommended. Manual differentials should count at least 400 cells.

For flow cytometric measures:

a. The optimal specimen for lymphocyte immunophenotyping by flow cytometry is either an EDTA-preserved whole blood specimen less than six hours old or a heparinized whole blood specimen up to 24 hours old.

b. Recognizing that laboratories may receive suboptimal (old) flow cytometric specimens, ASTPHLD recommends that laboratories verify the maximum age of specimens for which immunophenotyping results are comparable to fresh specimens.

c. Optimally, specimens should be maintained at room temperature (18°C to 22°C) until tested.

3.07 Whole blood lysis and two-color immunofluorescence are the methods of choice for flow cytometric immunophenotyping.

3.08 The ASTPHLD recommends the two-color monoclonal antibody panel specified in the Table for routine immunophenotyping.

### Table: Recommended Two-Color Monoclonal Antibody Panel for Routine Immunophenotyping

<table>
<thead>
<tr>
<th>Monoclonal Antibody Combination*</th>
<th>Cell Type Enumerated</th>
</tr>
</thead>
<tbody>
<tr>
<td>IgG&lt;sub&gt;1&lt;/sub&gt;/IgG&lt;sub&gt;2&lt;/sub&gt;</td>
<td>Isotype controls</td>
</tr>
<tr>
<td>CD45/CD14</td>
<td>Percent lymphocytes in gating region†</td>
</tr>
<tr>
<td>CD3/CD4</td>
<td>Thelper/inducer subset‡</td>
</tr>
<tr>
<td>CD3/CD8</td>
<td>Tsuppressor/cytotoxic subset‡</td>
</tr>
<tr>
<td>CD3/CD16 + CD56</td>
<td>Total T cells/total NK cells**</td>
</tr>
<tr>
<td>CD197</td>
<td>Total B-cells</td>
</tr>
</tbody>
</table>

* FITC/PE-labeled reagents.
† Lymphocytes will be CD45<sup>bright</sup>CD14<sup>negative</sup>.
‡ Indicated cell type will be positive for both antibodies.
**Total T cells = all cells expressing CD3; total NK cells = all cells that are CD3-negative but positive for CD16 and/or CD56.

3.09 Lymphocyte light scatter gates must be validated by anti-CD45 (pan-leukocyte) and anti-CD14 (monocyte) reactivity.

a. Optimally, nonlymphocyte contamination within the gate should not exceed 5%. Eighty-five percent is the lower limit of acceptable lymphocyte representation in the lymphocyte gate.

b. At least 95% of lymphocytes should be contained within the light scatter gate.

3.10 Lymphocyte subset percentage values from the flow cytometer should be corrected by dividing the observed percentage by the percentage of lymphocytes (CD45<sup>bright</sup>CD14<sup>negative</sup>) in the lymphocyte gating region.

3.11 For most specimens, the total of the corrected CD<sub>3</sub><sup>positive</sup> (Total T), CD19<sup>positive</sup> (Total B), and CD<sub>3</sub><sup>negative</sup> CD56<sup>positive</sup> and/or CD16<sup>positive</sup> (Total NK) percentages should sum to between 95% and 105%.

3.12 Each laboratory must establish age-and population-appropriate reference ranges in accordance with validated statistical criteria.

a. It should be noted that pediatric reference ranges may differ substantially from the reference ranges for adult populations.

3.13 The manufacturers of flow cytometry instrumentation and reagents are urged to cooperatively expedite the development of:

a. Improved lymphocyte gating reagents.

b. Automated sample preparation technology.

c. Flow cytometers capable of determining absolute numbers for lymphocyte subsets.

d. Improved laboratory quality control reagents.
e. Anticoagulants and preservatives suitable for both hematologic and flow cytometric measurements.

3.14 Laboratory reports should optimally include lymphocyte subset percentages, absolute values, and laboratory reference ranges.

a. Laboratory reports should specify the immunophenotype (CD designation) for all lymphocyte subsets reported therein (e.g., Thelper/inducer = CD3positive/CD4positive).

b. Values for lymphocyte subsets should be corrected for the lymphocyte representation in the gating region.

c. Absolute values for lymphocyte subsets should be reported unless hematologic results are suspect.

3.15 The ASTPHLD strongly supports efforts by the Centers for Disease Control to establish a national lymphocyte immunophenotyping performance evaluation program including training and education programs.

3.16 The ASTPHLD strongly supports the efforts of the NCCLS and the NIAID Flow Cytometry Advisory Committee in setting standards for clinical flow cytometric immunophenotyping.

3.17 The ASTPHLD encourages the development of alternative (nonflow cytometric) methods for the enumeration of CD4+ lymphocytes.

TESTING (HIV-2, HTLV-I/II)

CHAIR
Chyang Fang, PhD, Director, National Reference Laboratory for Infectious Diseases, American Red Cross, Rockville, Maryland.

MEMBERS
J. Richard George, PhD, Chief, Developmental Technology Section, Centers for Disease Control, Atlanta, Georgia; Jonathan Kaplan, MD, Retrovirus Diseases Branch, Centers for Disease Control, Atlanta, Georgia; Helen Lee, PhD, Director, Transfusion Biology Research and Development, Abbott Laboratories, North Chicago, Illinois (Rapporteur); Roy Stevens, PhD, Director of Laboratories for Diagnostic Immunology, New York State Department of Health, Albany, New York; Barbara Werner, PhD, Director, Clinical Investigation and Virology, State Laboratory Institute, Boston, Massachusetts.

TOPICS
HTLV-I and HTLV-II differentiation; confirmation methodology and criteria for HIV-1/HIV-2 and HTLV-I/II; HIV-1/HIV-2 combination tests; rapid testing methods.

RECOMMENDATIONS
4.01 We encourage manufacturers to develop second-generation confirmatory tests to replace the current WB-RIPA procedures with assays utilizing recombinant proteins and/or synthetic peptides in formats that allow objective reading.
4.02 The inclusion of p19+gp46/61 pattern as confirmatory for HTLV-I/II seropositivity should be further evaluated.
4.03 The utility of p21e in the current confirmation criteria needs to be validated; the specificity of recombinant p21e, in particular, should be further evaluated.
4.04 Since HTLV-I and HTLV-II infections have different disease manifestations, we recommend that public health laboratories carry out, if possible, routine differentiation of HTLV-I from HTLV-II in HTLV-I/II seropositive samples.
4.05 We encourage the development and evaluation of recombinant and/or synthetic peptide reagents for the differentiation of HTLV-I from HTLV-II antibodies.
4.06 We recognize that current HTLV-I screening assays will occasionally fail to detect HTLV-II antibodies and encourage systematic epidemiological and laboratory studies to determine the sensitivity of HTLV-I reagents for HTLV-II antibody detection. If a sizable percentage of HTLV-II antibodies are missed, the development of a more sensitive second-generation HTLV assay is recommended.
4.07 National surveillance for HIV-2 infections should be continued.
4.08 HIV-1 seronegative or indeterminate persons with AIDS-related symptoms or those at risk for HIV-2 infection should be considered as candidates for HIV-2 antibody testing.
4.09 Upon the availability of HIV-1/HIV-2 combination tests, the public health laboratories should consider the importance of adopting the combination assays based on epidemiological data pertinent to the local area.
4.10 The ASTPHLD Committee on Human Retrovirus Testing should appoint a committee composed of representatives from public health laboratories and manufacturers to determine the characteristics of standard HIV-2 confirmatory tests. For example, for western blot, these would include the virus strain, purification and processing of antigens, and interpretive criteria.

DIAGNOSIS OF HIV INFECTION IN NEWBORNS

CHAIR
Sara Beatrice, PhD, Director of Retrovirology and Immunology, New York City Department of Public Health, New York, New York.

MEMBERS
Anne M. Comeau, PhD, Co-Principal Investigator, Newborn HIV Project, Theobald Smith Research Institute, Jamaica Plain, Massachusetts; Francis Lee, MD, Assistant Professor of Pediatrics, Pediatric Infectious Diseases, Emory University, Atlanta, Georgia; Barbara Weiblen, MS, Senior Scientist, Newborn HIV Project, Theobald Smith Research Institute, Jamaica Plain, Massachusetts.

TOPICS
Flow cytometry; polymerase chain reaction and culture assays; ELISPOT and in vitro assays; IgA and other serologic assays.

RECOMMENDATIONS
5.01 The committee recommends the continuation of prospective studies for evaluation of relevant tests for the early diagnosis of infection, especially to identify rapid progressors. Prospective studies should include comparison analysis of PCR, culture, ELISPOT, and HIV-specific IgA antibodies.

5.02 PCR appears to be the most sensitive test for diagnosis of HIV infection in the first three months of life.

5.03 Negative results obtained on specimens from infants less than one month of age must be regarded as tentative. Additional specimens should be tested from these infants at ages greater than one month. Positive results obtained within the first month of life must be confirmed with tests on an independent specimen as soon as possible (preferably in the first two months of life). All positive PCR results, regardless of age, should be confirmed with tests on an independent specimen.

5.04 Virus culture is an effective tool for diagnosis of HIV infection in young children. A negative result does not rule out infection; a positive result should be confirmed.

5.05 ELISPOT is a promising new test for the diagnosis of infection in infants in the first three months of life. It may complement PCR testing during the neonatal period. The committee recommends further testing on early specimens to evaluate its predictive value.

5.06 IgA HIV antibody tests are of limited diagnostic value in neonates but may be positive by three months of age. Because the IgA test is a simple modification of existing technology, it may be useful as a supplemental test in regional laboratories.

STANDARDS OF PRACTICE

CHAIR

Dale Lawrence, MD, Chief, Clinical Development Section, Vaccine Research and Development Branch, Basic Research and Development Program, Division of AIDS, National Institute of Allergy and Infectious Diseases, Rockville, Maryland.

MEMBERS

Susan Mottice, PhD, Director, Microbiology, Utah State Health Department, Salt Lake City, Utah; Lt. Col. Chester Roberts, PhD, Chief, Diagnostic Retrovirology, Walter Reed Army Institute of Research, Rockville, Maryland; Judith Wethers, MS, Director, Testing Services, Retrovirology Laboratory, State of New York Department of Health Laboratories, Albany, New York; Keith Lawrence, Administrator, New York City Department of Health, New York, New York (Rapporteur).

TOPICS

Reporting; testing of vaccinated individuals.

RECOMMENDATIONS

6.01 This workshop reaffirms the reporting procedures recommended by the Fifth Consensus Conference, with the addition by reference to Section 9.02f. Item 2: “A narrative laboratory interpretation, including a reference to immune response elicited by vaccines.”

6.02 We welcome the drafting by CAP of anti-HIV test reporting guidelines and encourage all ASTPHLD attendees to review and provide feedback to CAP.

6.03 Persons interpreting western blot tests should be aware that participation by initially seronegative volunteers in clinical trials of HIV/AIDS vaccines will likely result in the acquisition of detectable immune responses to HIV. These responses may include the development of a positive ELISA test and western blot bands reflecting the antigenic formulation and immunogenicity of the vaccine. Some vaccines may induce western blot bands which meet published criteria for a positive test.

6.04 During succeeding years, the testing of various types of vaccine formulations can be anticipated. To preclude misclassification of a vaccinated volunteer with a positive HIV antibody test result as infected, it will be necessary that interpretation take into account the past HIV vaccine immunization history. To assist in this, the following procedures should be implemented by HIV/AIDS vaccine investigators.

a. At the conclusion of a trial, volunteers should be provided with information on the vaccine formulation(s) administered along with, as a minimum, the results of their ELISA and western blot tests post-vaccination.

b. Participants should have long-term accessibility to this information with safeguards to protect confidentiality.

6.05 The NIH is supported in its effort to develop for publication, in concert with the CDC and other relevant agencies, an MMWR advisory acknowledging the unique circumstances surrounding HIV/AIDS vaccine study participation.
1. **J.E. Johnson.** Comparison of Whole Cell Viral Lysate (VL), Synthetic Peptide (SP), and Recombinant Protein (RCP) EIA for Detection of HIV-1 Antibody.


3. **C. Ferrera, N. Dock, J. Huprikar, J. Phair, M. Krieger.** Use of a Peptide-Based, Rapid Immunoblot Assay for Antibody to HIV-1 to Clarify True Antibody Status of EIA Repeat Reactive, Western Blot Indeterminate.

4. **W. Link.** Effect of Nonspecific Glycoprotein Bands on Interpretation of HIV-1 Western Blots.

5. **B.P. Griffith, T.M. Chacko.** Comparative Performance of Peptide, Recombinant and Viral Lysate-Based Enzyme Immunosorbent Assays for the Detection of HIV-1 Antibody.


10. **J. Gregg, C. Ludvigsen, B. Roberts.** Detection of Antibodies Directed to HIV-1 in Oral Mucosal Transudate.


16. **M.T. Ramirez, N.S. Swack, W.J. Hausler, Jr.** Reactivity of Six Commercial HIV-1 EIA Test Procedures on Western Blot Indeterminate Sera.


23. **J.A. Connell, J.V. Parry, P.P. Mortimer.** IgG Antibody Capture ELISA A Diagnostic Test for Anti-HIV Applicable to All Body Fluids.


27. A.M. Comeau, B. Weiblen J.A. Harris, K. McIntosh, R. Hoff. Analysis of Early Infant Specimens by the Polymerase Chain Reaction (PCR) for the Detection of HIV-1 Proviral DNA.


29. J. Ackerman, W. Link. Effect of Including gp21 in Interpretation Criteria for HTLV-I Western Blot.


33. B. Weiblen, A. Comeau. Early Diagnosis of HIV Infection in Infants by Detection of IgA and IgM HIV Antibodies.


36. D. Gallo, P.J. Dailey, C.V. Hanson. Antigenicity of New HTLV-II-Infected Cell Lines Derived from California IVDU.
